附件10.1

證券購買 協議

這證券購買協議(“協議”)日期為2023年8月31日，由Lytus Technologies Holdings PTV簽署。本公司為根據英屬維爾京羣島法律成立的公司，其辦事處位於印度孟買Andheri(East) Andheri(East) Andheri(East)，Mahakali Caves Road A翼601號珠峯格蘭德(Everest Grande)(“本公司”)，以及本協議所附買家名單上所列的每一位投資者(個別為“買家”，集體為“買家”)。

獨奏會

答： 公司和每個買方依據的是《1933年證券法》(經修訂)第4(A)(2)節和美國證券交易委員會(“美國證券交易委員會”)根據1933年法案頒佈的《條例D》第506(B)條規定的證券登記豁免 簽署和交付本協議。

B.公司已授權本公司新發行的一系列可轉換優先股，指定為A系列可轉換優先股，面值為0.01美元，其條款載於該系列優先股的指定證書(“指定證書”)中，其形式為附件A(連同根據其條款發行的任何可轉換優先股，即“A系列優先股”)。A系列優先股 可轉換為普通股(定義見下文)(根據指定證書的條款可發行的普通股，包括但不限於轉換或以其他方式統稱為“轉換股份”)， 根據指定證書的條款。

C.每個買方都希望購買，而公司希望根據本協議規定的條款和條件出售(I)買方名單第(3)欄中與買方姓名相對的A系列優先股(“初始優先股”)股份總數，(Ii)初步收購買方名單第(5)欄中與買方姓名相對的額外普通股總數的普通權證。實質上以附件 B(“普通權證”)(統稱為“認股權證”)的形式及 (Iii)認股權證，初步收購買方名冊第(4)欄內與買方姓名相對的A系列優先股額外股份總數，基本上以附件附件作為附件C(“優先認股權證”)的形式(統稱為“認股權證”)(行使時為“認股權證”，連同初始優先股，稱為“優先股”)。

D.在交易結束時，本協議各方應簽署並交付一份註冊權協議，該協議的格式應為本協議附件D(“註冊權協議”)，根據該協議，公司同意根據1933年法案及其頒佈的規則和法規以及適用的州證券法，就可註冊證券(在註冊權協議中的定義)提供某些註冊權利。

E.優先股、轉換股份、優先認股權證、普通權證及認股權證在此統稱為“證券”。

協議書

因此，本公司和每一位買主在此確認，考慮到房屋和本合同所載的相互契諾，以及其他良好和有價值的對價，已收到並已收到足夠的價款，本公司和每位買方同意如下：

1.優先股、優先權證及普通權證的買賣。

(A) 購買優先股、優先權證和普通權證。在滿足(或豁免)以下第6條和第7條規定的條件的前提下，公司應向每一位買家發行並出售，每一位買家分別但不是共同同意 在成交日期(定義如下)從本公司購買(A)在買家名單第(3)欄中與買家姓名相對的優先股總數。(B)優先認股權證，初步收購買方附表第(4)欄中與買方姓名相對的認股權證優先股總數 ，及(C)普通權證 ，初步收購買方附表第(5)欄中與買方姓名相對的認股權證普通股總數。

(B) 結束。買方購買優先股、優先認股權證和普通權證的交易應在Kelley Drye&Warren LLP的辦公室進行，地址為紐約格林威治街175號，紐約，NY 10007。成交日期及時間(“成交日期”)應為紐約時間上午10：00，即滿足或豁免下文第6及7節所載成交條件的首(1)個營業日(或本公司與各買方雙方同意的其他 日期)。這裏所用的“營業日”是指除星期六、星期日或法律授權或要求紐約市商業銀行繼續關閉的其他日子以外的任何日子；但為澄清起見，只要紐約市商業銀行的電子資金轉賬系統(包括電匯系統)在這一天對客户開放，商業銀行不應被視為獲得授權或法律要求其繼續關閉，只要該日紐約商業銀行的電子資金轉賬系統(包括電匯系統)在這一天對客户開放。

(C) 採購價格。各買方將購買的優先股、優先認股權證及普通權證的總收購價(“收購價”)應為買方名單第(6)欄中與該買方名稱相對的金額。每名買方應為其將在成交時購買的每1,000美元的優先股、優先認股權證和普通權證支付約850美元。

(D)付款形式。在成交日期，(I)每個買方應向公司支付各自的購買價格(如果是任何買方，則減去根據第4(G)條扣留的 金額)，以購買將在成交時發行和出售給該買方的優先股、優先認股權證和普通權證，根據《資金流動函》(定義見下文)，通過電匯立即可用資金，以及(Ii)公司應向每位買方交付(A)買方名單第(3)欄中與買方姓名相對的優先股總數，(B)向 初步收購於買方附表第(4)欄與買方姓名相對之處所載最多該總數認股權證優先股及(C)普通權證，據此，該買方有權初步收購於買方附表第(5)欄與買方姓名相對之該等認股權證普通股總數，在每種情況下，該優先認股權證均代表本公司妥為籤立，並登記於該買方或其指定人名下。

2. 買方陳述和保修。

每名買方(並非共同)僅就其本身向本公司表示並保證，截至本合同日期和截止日期：

(A)組織；權威。該買方是根據其組織的法律正式組織、有效存在和信譽良好的實體，具有必要的權力和授權以達成和完成其所屬的交易文件(定義見下文)所設想的交易，並以其他方式履行其在本協議和協議項下的義務。

(b) No Public Sale or Distribution. Such Buyer (i) is acquiring its Preferred Shares, Preferred Warrant and Common Warrants, (ii) upon conversion of its Preferred Shares will acquire the Conversion Shares issuable upon conversion thereof, (iii) upon exercise of its Common Warrants (other than pursuant to a Cashless Exercise (as defined in the Common Warrants)) will acquire the Warrant Common Shares issuable upon exercise thereof and (iv) upon exercise of its Preferred Warrants will acquire the Warrant Preferred Shares issuable upon exercise thereof, in each case, for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by making the representations herein, such Buyer does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption from registration under the 1933 Act. Such Buyer does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities in violation of applicable securities laws. For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity (as defined below) or any department or agency thereof.

(c)認可 投資者狀態。該買方是一個“認可投資者”，該術語定義在條例D的規則501（a）。

(d)依賴豁免。 該買方理解，根據美國聯邦和州證券法的註冊要求的特定豁免，向其提供和出售證券，且該公司部分依賴於聲明、保證、協議的真實性和準確性， 以及該買方遵守這些聲明、保證、協議，本協議所述買方的同意和理解 ，以確定此類豁免的可用性以及買方收購證券的資格。

(e)信息. 該買方及其顧問（如有）已被提供了與 公司業務、財務和運營有關的所有材料，以及與該買方要求的證券要約和銷售有關的材料。此類買方及其 顧問（如有）有機會向公司提出問題。買方或其顧問（如有）或其代表進行的此類查詢或任何其他盡職調查均不得修改、修改或影響買方依賴本協議所載公司聲明和保證的權利。該買方明白其 投資證券涉及高度風險。該買方已尋求其 認為必要的會計、法律和税務建議，以就其收購證券作出明智的投資決定。

(f)沒有政府審查。 該買方理解，美國聯邦或州機構或任何其他政府或政府機構均未就證券或證券投資的公平性或適當性傳遞或 作出任何建議或認可，也未 該等機構傳遞或認可證券發行的價值。

(g) Transfer or Resale. Such Buyer understands that except as provided in the Registration Rights Agreement and Section 4(h) hereof: (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) such Buyer shall have delivered to the Company (if requested by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) such Buyer provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document (as defined in Section 3(b)), including, without limitation, this Section 2(g).

(h)有效性； 強制執行。本協議和註冊權協議已代表該買方正式有效授權、簽署和交付 ，並構成該買方的合法、有效和有約束力的義務，可根據其各自的條款對該買方執行 ，除非此類可執行性可能受到一般公平原則的限制，或 適用的破產、無力償債、重組、延期，清算和其他與執行適用債權人權利和救濟措施有關或普遍影響的類似法律。

(i)沒有衝突。 該買方對本協議和註冊權協議的執行、交付和履行，以及該 買方完成本協議所設想的交易，因此不會（i）導致違反該 買方的組織文件，或（ii）與該 買方的組織文件相沖突，或構成違約（或經通知或時間流逝或兩者均將成為違約的事件） 或給予他人終止、修訂、加速或取消該買方作為一方的任何協議、標識或文書的任何權利，或（iii）導致違反任何法律、規則、規例、命令、判決或判令（包括聯邦 和州證券法）適用於該買方，但上文第（ii）和（iii）款除外，對於此類衝突、違約、 權利或侵權行為，這些衝突、違約、 權利或侵權行為不能單獨或總體，合理預期會對買方履行其在本協議項下義務的能力產生重大不利影響。

(j)住院醫生該 買方是買方列表中其地址下方指定的該管轄區的居民。

3. 公司的陳述和擔保。

本公司聲明並 向各買方保證，截至本協議日期和截止日期：

(a) Organization and Qualification. Each of the Company and each of its Subsidiaries are entities duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below). As used in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary (as defined below), individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or instruments to be entered into in connection herewith or therewith or (iii) the authority or ability of the Company or any of its Subsidiaries to perform any of their respective obligations under any of the Transaction Documents (as defined below). Other than the Persons (as defined below) set forth on Schedule 3(a), the Company has no Subsidiaries. “Subsidiaries” means any Person in which the Company, directly or indirectly, (I) owns any of the outstanding share capital or holds any equity or similar interest of such Person or (II) controls or operates all or any part of the business, operations or administration of such Person, and each of the foregoing, is individually referred to herein as a “Subsidiary.”

(b) Authorization; Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents by the Company, and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Preferred Shares and the reservation for issuance and issuance of the Conversion Shares issuable upon conversion of the Preferred Shares, the issuance of the Common Warrants and the reservation for issuance and issuance of the Warrant Common Shares issuable upon exercise of the Common Warrants and the issuance of the Preferred Warrants and the reservation for issuance and issuance of the Warrant Preferred Shares issuable upon exercise of the Preferred Warrants) have been duly authorized by the Company’s board of directors or other governing body, as applicable, and (other than the filing with the SEC of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, a Form D with the SEC and any other filings as may be required by any state securities agencies) no further filing, consent or authorization is required by the Company, its Subsidiaries, their respective boards of directors or their shareholders or other governing body. This Agreement has been, and the other Transaction Documents to which it is a party will be prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law. The Certificate of Designations in the form attached hereto as Exhibit A has been approved by the board of directors of the Company and is authorized under the Articles of Association (as defined below), and is in full force and effect, enforceable against the Company in accordance with its terms and has not have been amended. “Transaction Documents” means, collectively, this Agreement, the Preferred Shares, the Common Warrants, the Preferred Warrants, the Certificate of Designations, the Registration Rights Agreement, the Irrevocable Transfer Agent Instructions (as defined below) and each of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

(c) Issuance of Securities. The issuance of the Initial Preferred Shares are duly authorized and upon issuance in accordance with the terms of the Transaction Documents shall be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances, security interests and other encumbrances (collectively “Liens”) with respect to the issuance thereof. The issuance of the Preferred Warrants and the Common Warrants are duly authorized and upon issuance in accordance with the terms of the Transaction Documents shall be validly issued and free from all Liens with respect to the issuance thereof. As of the Closing, the Company shall have reserved from its duly authorized share capital not less than the sum of (i) the maximum number of Conversion Shares issuable upon conversion of the Preferred Shares (assuming for purposes hereof that (w) the Preferred Warrants have been exercised in full, (x) the Preferred Shares are convertible at the Floor Price (as defined in the Certificate of Designations) and (y) any such conversion shall not take into account any limitations on the conversion of the Preferred Shares set forth in the Certificate of Designations), (ii) the maximum number of Warrant Preferred Shares initially issuable upon exercise of the Preferred Warrants (without taking into account any limitations on the exercise of the Preferred Warrants set forth therein) and (iii) the maximum number of Warrant Common Shares initially issuable upon exercise of the Common Warrants (without taking into account any limitations on the exercise of the Common Warrants set forth therein). Upon issuance or conversion in accordance with the Certificate of Designations or exercise in accordance with the Common Warrants or the Preferred Warrants (as the case may be), the Conversion Shares, the Warrant Common Shares and the Warrant Preferred Shares, respectively, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Shares or Preferred Shares, as the case may be. Subject to the accuracy of the representations and warranties of the Buyers in this Agreement, the offer and issuance by the Company of the Securities is exempt from registration under the 1933 Act.

(d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Initial Preferred Shares, the Common Warrants, the Preferred Warrants, the Conversion Shares, the Warrant Common Shares and the Warrant Preferred Shares and the reservation for issuance of the Conversion Shares, the Warrant Common Shares and the Warrant Preferred Shares) will not (i) result in a violation of the Articles of Association (as defined below) (including, without limitation, any certificate of designation contained therein), Memorandum of Association (as defined below), certificate of formation, memorandum of association, articles of association, bylaws or other organizational documents of the Company or any of its Subsidiaries, or any share capital or other securities of the Company or any of its Subsidiaries, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations and the rules and regulations of the Nasdaq Capital Market (the “Principal Market”) and including all applicable foreign, federal and state laws, rules and regulations, including, without limitation, the laws, rules and regulations of British Virgin Islands and India) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected.

(e) Consents. Neither the Company nor any Subsidiary is required to obtain any consent from, authorization or order of, or make any filing or registration with (other than the filing with the SEC of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, a Form D with the SEC and any other filings as may be required by any state securities agencies), any Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its respective obligations under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been or will be obtained or effected on or prior to the Closing Date, and neither the Company nor any of its Subsidiaries are aware of any facts or circumstances which might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration, application or filings contemplated by the Transaction Documents. The Company is not in violation of the requirements of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of the Common Shares in the foreseeable future. “Governmental Entity” means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public international organization or any of the foregoing.

(f) Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that no Buyer is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate” (as defined in Rule 144) of the Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner” of more than 10% of the Common Shares (as defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934 Act”)). The Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Buyer’s purchase of the Securities. The Company further represents to each Buyer that the Company’s decision to enter into the Transaction Documents to which it is a party has been based solely on the independent evaluation by the Company, each Subsidiary and their respective representatives.

(g)無一般徵集； 安置代理費用。本公司、其任何子公司或關聯公司、或代表本公司或其 行事的任何人士均未就本公司的要約或出售進行任何形式的一般招攬或一般廣告（定義見法規D）。本公司應負責支付與本協議預期交易有關或產生 的任何配售代理費用、財務 諮詢費用或經紀人佣金（買方或其投資顧問聘用的人員除外）。公司應支付與任何此類索賠有關的任何責任、損失或費用 （包括但不限於律師費和自付費用），並使每個買方免受損害。 本公司或其任何子公司均未聘用任何配售代理或其他代理人進行證券的發售或出售。

(h)沒有集成的產品。 本公司、其子公司或其任何關聯公司，或代表其行事的任何人士，均未直接或間接地， 在需要根據1933年法案登記發行任何證券的情況下， 無論是通過與先前的發行整合或其他方式，或使 本次證券發行需要獲得公司股東的批准，以符合1933年法案或任何適用的 股東批准條款，包括但不限於根據任何交易所或自動報價系統的規則和條例，在其上上市或指定報價。本公司、其子公司、其 關聯公司或代表其行事的任何人士均不得采取任何行動或步驟，要求根據《1933年法案》（《登記權協議》除外）對任何 證券發行進行登記，或導致任何證券的發行 與本公司的其他證券發行合併。

絕對及無條件，不論該等發行對本公司其他股東的所有權權益可能產生的攤薄影響。

(j) 接管保護的應用；權利協議。本公司及其董事會已採取一切必要行動（如有），以 使任何控制權股份收購、有利害關係的股東、業務合併、毒丸（包括但不限於根據權利協議進行的任何分配）、股東權利計劃或 公司章程細則下的其他類似反收購條款，公司備忘錄或其他組織文件或其 註冊成立地所在司法管轄區的法律，或其他因本 協議中預期的交易而適用於或可能適用於任何買方的其他法律，包括但不限於，公司發行證券以及任何買方對 證券的所有權。公司及其董事會已採取一切必要行動（如有），以使任何 股東權利計劃或與普通股實益所有權累積或 公司或其任何子公司控制權變更有關的類似安排不適用。

(k) SEC Documents; Financial Statements. During the two (2) years prior to the date hereof, the Company has timely filed all reports, schedules, forms, proxy statements, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof and all exhibits and appendices included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”). The Company has delivered or has made available to the Buyers or their respective representatives true, correct and complete copies of each of the SEC Documents not available on the EDGAR system. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate). The reserves, if any, established by the Company or the lack of reserves, if applicable, are reasonable based upon facts and circumstances known by the Company on the date hereof and there are no loss contingencies that are required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards Board which are not provided for by the Company in its financial statements or otherwise. No other information provided by or on behalf of the Company to any of the Buyers which is not included in the SEC Documents (including, without limitation, information referred to in Section 2(e) of this Agreement or in the disclosure schedules to this Agreement) contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the light of the circumstance under which they are or were made. The Company is not currently contemplating to amend or restate any of the financial statements (including, without limitation, any notes or any letter of the independent accountants of the Company with respect thereto) included in the SEC Documents (the “Financial Statements”), nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with IFRS and the rules and regulations of the SEC. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.

(L)沒有某些 變化。自本公司最近一份經審核財務報表載於20-F表格之日起，本公司或其任何附屬公司的業務、資產、負債、物業、營運(包括其業績)、狀況(財務或其他)或前景並無重大不利變化及重大不利發展。自本公司最近一份經審核財務報表載於20-F表格的日期起，本公司或其任何附屬公司概無(I)宣佈或 派發任何股息、(Ii)在正常業務過程以外個別或合共出售任何資產，或(Iii)在正常業務過程以外單獨或合計作出任何資本開支。本公司或其任何附屬公司並無根據任何有關破產、無力償債、重組、接管、清盤或清盤的法律或法規採取任何步驟尋求保障，本公司或任何附屬公司亦不知悉或有理由相信其各自的任何債權人有意啟動非自願破產程序，或實際知悉任何事實而合理地 導致債權人這樣做。本公司及其附屬公司，以個別及綜合基準計算，於本協議日期並非無力償債， 在實施預期於結算時進行的交易後，將不會無力償債(定義見下文)。就本第3節(L)而言，“破產”是指：(1)就本公司及其附屬公司而言，綜合 基礎上，(A)本公司及其附屬公司資產目前的公允可出售價值低於償還本公司及其附屬公司的總債務(定義見下文)所需的金額，(B)本公司及其附屬公司 無法償還其從屬、或有或有或以其他方式承擔的債務和負債，當該等債務及負債變為絕對及到期時 或(C)本公司及其附屬公司打算招致或相信他們將招致的債務將超過其償還能力 ；及(Ii)就本公司及各附屬公司個別而言，(A)本公司或該附屬公司(視屬何情況而定)的資產目前的公平可出售價值低於支付其各自的債務總額所需的金額，(B)本公司或該附屬公司(視屬何情況而定)無力償還其各自的債務及負債，不論是從屬的、或有的或有的或有或有的，當該等債務及負債成為絕對及到期債務，或(C)本公司或該等附屬公司(視情況而定)有意或相信將會產生超過其各自償債能力的債務。 本公司或其任何附屬公司均未從事任何業務或任何交易，亦不會從事任何 業務或任何交易。本公司或該附屬公司的剩餘資產構成進行其所從事的業務的資本不合理地少 ，因為該等業務現已進行及擬進行。

(M)無任何未披露的事件、責任、發展或情況。本公司、其任何子公司或其各自的任何業務、財產、負債、前景、運營(包括其結果)或狀況(財務或其他)未發生或 不存在或 存在或發生的事件、責任、發展或情況， (I)根據適用的證券法，本公司須在向美國證券交易委員會提交的與本公司發行和出售其普通股有關的F-1表格登記聲明中披露 (I)，且尚未公開宣佈，(Ii) 可能對買方在本合同項下的任何投資產生重大不利影響，或(Iii)可能產生重大不利影響。

(n) Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default under its Articles of Association, any certificate of designation, preferences or rights of any other outstanding series of preferred shares of the Company or any of its Subsidiaries or Memorandum of Association or their organizational charter, certificate of formation, memorandum of association, articles of association, Articles of Association or certificate of incorporation or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect. Without limiting the generality of the foregoing, the Company is not in violation of any of the rules, regulations or requirements of the Principal Market and has no knowledge of any facts or circumstances that could reasonably lead to delisting or suspension of the Common Shares by the Principal Market in the foreseeable future. During the two years prior to the date hereof, (i) the Common Shares has been listed or designated for quotation on the Principal Market, (ii) trading in the Common Shares has not been suspended by the SEC or the Principal Market and (iii) the Company has received no communication, written or oral, from the SEC or the Principal Market regarding the suspension or delisting of the Common Shares from the Principal Market. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries.

(o)海外腐敗 做法。公司、公司子公司或任何董事、高級管理人員、代理人、僱員或任何其他代表上述人員 （單獨和集體，稱為"公司關聯公司"）違反了 美國反海外腐敗法（“FCPA”）或任何其他適用的反賄賂或反腐敗法律， 任何公司關聯公司也沒有提供、支付或承諾支付，或授權支付任何金錢，或提議、給予、承諾給予或授權給予任何有價值的東西給任何官員、僱員或以任何政府實體的官方身份行事的任何其他人給任何政黨或其官員或任何政治職位候選人（單獨和 統稱為"政府官員"）或在該公司關聯公司知道或 意識到將直接或間接提供、給予或承諾全部或部分此類金錢或有價值物品的可能性很高的情況下， 向任何政府官員提供，目的是：

(i)（A）影響 該政府官員以其官方身份的任何行為或決定，（B）誘使該政府官員作出或不作出任何違反其合法職責的行為，（C）獲取任何不正當利益，或（D）誘使該政府官員影響 或影響任何政府實體的任何行為或決定，或

(ii)協助 公司或其子公司為公司或其子公司獲得或保留業務，或向公司或其子公司提供業務。

(p)薩班斯—奧克斯利法案 本公司及各子公司均遵守2002年《薩班斯—奧克斯利法案》（經修訂）的任何及所有適用要求， 以及美國證券交易委員會根據該法案頒佈的任何及所有適用規則和法規。

(q) Transactions With Affiliates. No current or former employee, partner, director, officer or shareholder (direct or indirect) of the Company or its Subsidiaries, or any associate, or, to the knowledge of the Company, any affiliate of any thereof, or any relative with a relationship no more remote than first cousin of any of the foregoing, is presently, or has ever been, (i) a party to any transaction with the Company or its Subsidiaries (including any contract, agreement or other arrangement providing for the furnishing of services by, or rental of real or personal property from, or otherwise requiring payments to, any such director, officer or shareholder or such associate or affiliate or relative Subsidiaries (other than for ordinary course services as employees, officers or directors of the Company or any of its Subsidiaries)) or (ii) the direct or indirect owner of an interest in any corporation, firm, association or business organization which is a competitor, supplier or customer of the Company or its Subsidiaries (except for a passive investment (direct or indirect) in less than 5% of the common equity of a company whose securities are traded on or quoted through an Eligible Market (as defined in the Certificate of Designations)), nor does any such Person receive income from any source other than the Company or its Subsidiaries which relates to the business of the Company or its Subsidiaries or should properly accrue to the Company or its Subsidiaries. No employee, officer, shareholder or director of the Company or any of its Subsidiaries or member of his or her immediate family is indebted to the Company or its Subsidiaries, as the case may be, nor is the Company or any of its Subsidiaries indebted (or committed to make loans or extend or guarantee credit) to any of them, other than (i) for payment of salary for services rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Company, and (iii) for other standard employee benefits made generally available to all employees or executives (including share option agreements outstanding under any share option plan approved by the Board of Directors of the Company).

(r)股權資本化。

(i)定義：

(A)"普通股"是指（x）公司的普通股，每股面值0.01美元，以及（y）該等普通股將被變更為的任何股本或因該等普通股重新分類而產生的任何股本。

(B)"優先股 "指（x）公司的空白支票優先股，每股面值0.01美元，其條款可由本公司董事會在指定證書中指定 ，以及（y）該等優先股將 變更為的任何股本或因該等優先股重新分類而產生的任何股本（根據該指定證書的條款將該等優先 股轉換為普通股除外）。

(ii)授權 和已發行股本。截至本協議日期，本公司的法定股本由230，000，000股普通股組成，其中40，568，554股已發行及已發行，18，361，474股已根據可轉換證券保留髮行。（定義見下文）（優先股和普通認股權證除外）可行使或交換或轉換為普通股 。本公司的庫務並無持有普通股。“可轉換證券”是指本公司或其任何子公司的任何股本 或其他證券，其可在任何時間和任何情況下直接或間接轉換 為本公司或其任何子公司的任何股本或其他證券，可行使或交換，或以其他方式使其持有人獲得本公司或其任何子公司的任何股本或其他證券 （包括但不限於普通股）。

(iii) Valid Issuance; Available Shares; Affiliates. All of such outstanding shares are duly authorized and have been, or upon issuance will be, validly issued and are fully paid and nonassessable. Schedule 3(r)(iii) sets forth the number of Common Shares that are (A) reserved for issuance pursuant to Convertible Securities (as defined below) (other than the Preferred Shares and the Common Warrants) and (B) that are, as of the date hereof, owned by Persons who are “affiliates” (as defined in Rule 405 of the 1933 Act and calculated based on the assumption that only officers, directors and holders of at least 10% of the Company’s issued and outstanding Common Shares are “affiliates” without conceding that any such Persons are “affiliates” for purposes of federal securities laws) of the Company or any of its Subsidiaries. To the Company’s knowledge, no Person owns 10% or more of the Company’s issued and outstanding Common Shares (calculated based on the assumption that all Convertible Securities (as defined below), whether or not presently exercisable or convertible, have been fully exercised or converted (as the case may be) taking account of any limitations on exercise or conversion (including “blockers”) contained therein without conceding that such identified Person is a 10% shareholder for purposes of federal securities laws).

(iv) Existing Securities; Obligations. Except as disclosed in the SEC Documents: (A) none of the Company’s or any Subsidiary’s shares, interests or share capital is subject to preemptive rights or any other similar rights or Liens suffered or permitted by the Company or any Subsidiary; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or share capital of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares, interests or share capital of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or share capital of the Company or any of its Subsidiaries; (C) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except pursuant to the Registration Rights Agreement); (D) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (E) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; and (F) neither the Company nor any Subsidiary has any share appreciation rights or “phantom share” plans or agreements or any similar plan or agreement.

（v） 組織文件。本公司已向買方提供真實、正確和完整的本公司公司章程（經修訂並於本協議日期生效）的副本（“公司章程”），以及經修訂並於本協議日期生效的公司章程，（“組織章程大綱”），以及所有可轉換 證券的條款及其持有人對該等證券的實質性權利。

(s) Indebtedness and Other Contracts. Neither the Company nor any of its Subsidiaries, (i) except as disclosed on Schedule 3(s), has any outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness of the Company or any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may become bound, (ii) is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result in a Material Adverse Effect, (iii) has any financing statements securing obligations in any amounts filed in connection with the Company or any of its Subsidiaries; (iv) is in violation of any term of, or in default under, any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect, or (v) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries have any liabilities or obligations required to be disclosed in the SEC Documents which are not so disclosed in the SEC Documents, other than those incurred in the ordinary course of the Company’s or its Subsidiaries’ respective businesses and which, individually or in the aggregate, do not or could not have a Material Adverse Effect. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (including, without limitation, “capital leases” in accordance with IFRS) (other than trade payables entered into in the ordinary course of business consistent with past practice), (C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which, in connection with IFRS, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; and (y) “Contingent Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto.

(t) Litigation. There is no action, suit, arbitration, proceeding, inquiry or investigation before or by the Principal Market, any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries, the Common Shares or any of the Company’s or its Subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such, except as set forth in Schedule 3(t). No director, officer or employee of the Company or any of its subsidiaries has willfully violated 18 U.S.C. §1519 or engaged in spoliation in reasonable anticipation of litigation. Without limitation of the foregoing, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company, any of its Subsidiaries or any current or former director or officer of the Company or any of its Subsidiaries. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the 1933 Act or the 1934 Act. After reasonable inquiry of its employees, the Company is not aware of any fact which might result in or form the basis for any such action, suit, arbitration, investigation, inquiry or other proceeding. Neither the Company nor any of its Subsidiaries is subject to any order, writ, judgment, injunction, decree, determination or award of any Governmental Entity.

（u） 保險。本公司及其子公司由具有公認財務責任的保險公司為 本公司及其子公司從事的業務中 本公司管理層認為謹慎和慣常的損失和風險投保。本公司或任何此類子公司均未被拒絕尋求或申請任何保險，且本公司或任何此類子公司均無理由相信，其將無法在現有的 保險到期時續延，或無法以不會產生重大不利影響的成本從類似保險公司獲得延續其業務所需的類似保險。

(v) Employee Relations. Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any member of a union. The Company and its Subsidiaries believe that their relations with their employees are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of the Company or any of its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary. No current (or former) executive officer or other key employee of the Company or any of its Subsidiaries is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer or other key employee (as the case may be) does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

(W)頭銜。

(i)不動產。 公司及其子公司對公司或其子公司擁有或持有的所有不動產、不動產租賃、設施或其他權益 公司或其子公司擁有 或其子公司（如適用）。不動產不受任何留置權的限制，不受任何道路權、 建築物使用限制、例外、差異、保留或任何性質的限制，但（a）尚未 到期的現行税收的留置權和（b）分區法律和其他土地使用限制，這些限制不會損害受其約束的財產的當前或預期用途 。本公司或其任何子公司根據租賃持有的任何不動產均由本公司或其任何子公司根據有效、存續和可執行的 租賃持有，但不屬重大且不影響本公司或其任何子公司對此類不動產和建築物的使用 。

(ii)夾具 和設備。公司及其子公司（如適用）對 公司或其子公司在開展業務時使用的 有形個人財產、設備、改進、固定裝置和其他個人財產和附屬物（“固定裝置和設備”）擁有良好的所有權或有效的租賃權益。 固定裝置和設備結構良好，運行狀況良好，維修良好，足以滿足其 的用途，除了普通的日常維護和維修外，不需要維護或維修，並且足以 以 關閉前的方式開展公司和/或其子公司的業務（如適用）。公司及其子公司擁有其所有固定裝置和設備，不受任何留置權的限制，但（a） 尚未到期的現行税款的留置權和（b）分區法和其他土地使用限制，這些限制不會損害受其約束的財產的當前或 使用。

(X)知識產權 權利。本公司及其附屬公司擁有或擁有足夠的權利或許可，以使用所有商標、商號、服務標誌、服務標誌註冊、服務名稱、原創作品、專利、專利權、版權、發明、許可、批准、政府授權、商業祕密和其他知識產權，以及開展其目前和目前擬開展的各自業務所需的所有申請和註冊(“知識產權”)。 本公司或其任何附屬公司擁有的每項專利列於附表3(X)(I)。除附表3(X)(Ii)所述外，自本協議之日起三年內，公司的任何知識產權均未到期、終止、放棄或預計將到期、終止或預計將放棄。本公司不知道 本公司或其子公司侵犯他人知識產權。本公司或其任何附屬公司並無就其知識產權向本公司或其任何附屬公司提出或提出任何索賠、訴訟或法律程序，或據本公司或其任何附屬公司所知而受到威脅。本公司及其任何附屬公司均不知悉可能導致任何前述侵權或索賠、訴訟或訴訟的任何事實或 情況。本公司及其子公司 已採取合理的安全措施保護其所有知識產權的保密性、保密性和價值。

(Y)環境法律。(I)本公司及其附屬公司(A)遵守任何及所有環境法律(定義見下文)，(B) 已收到適用環境法律要求其開展各自業務所需的所有許可證、牌照或其他批准，及(C)遵守任何該等許可證、許可證或批准的所有條款及條件，而上述條款(A)、(B)及(C)中的每一項均可合理地預期未能遵守會對個別或整體造成重大不利影響。“環境法”是指與污染或保護人類健康或環境(包括但不限於環境空氣、地表水、地下水、地表或地下地層)有關的所有聯邦、州、地方或外國法律，包括但不限於與向環境排放、排放化學品、污染物、污染物或有毒或危險物質或廢物(統稱為“危險材料”)有關的法律，或與製造、加工、分配、使用、處理、儲存、處置或處置有關的法律。危險材料的運輸或搬運，以及根據其發佈、登記、頒佈或批准的所有授權、守則、法令、要求或要求函、禁令、判決、許可證、通知或通知信、命令、許可證、計劃或條例。

(ii)無危險材料：

(A)已 違反任何 環境法，處置或以其他方式從公司或其任何子公司的任何不動產中釋放；或

(B) 存在於任何不動產或其任何部分之上、之上、之下、之內或之上，其數量將構成違反任何環境法的 。本公司或其任何附屬公司先前並無使用任何不動產違反任何環境法律，而違反該等法律會對本公司或其任何附屬公司的業務產生重大不利影響。

(Iii)本公司或其任何附屬公司均不知悉任何其他人士或實體在任何不動產上儲存、處理、回收、處置或以其他方式處置任何危險物質，包括但不限於石棉和多氯聯苯等物質。

(Iv)這些房地產不在任何聯邦或州“超級基金”名單或責任信息系統(“CERCLIS”)名單上，也不在任何州環保局考慮申請CERCLIS的地點名單上，也不受 任何與環境有關的留置權的約束。

(Z)附屬權利。 本公司或其附屬公司享有不受限制的投票權，並(受適用法律所施加的限制) 收取本公司或該附屬公司所擁有的附屬公司的所有資本證券的股息及分派。

(Aa)納税狀況。 本公司及其每一子公司(I)已及時提交或提交其所屬司法管轄區要求的所有外國、聯邦和州收入及所有其他税收、報告和申報，(Ii)已及時支付所有税款和其他政府評估和收費，這些納税和收費在金額上是實質性的，並在該等申報、報告和申報中顯示或確定為應繳，除非出於善意提出異議，並且(Iii)已在其賬面上留出合理充足的撥備，以便在該等申報表、報告或聲明適用的期間之後的期間內繳納所有税款。任何司法管轄區的税務機關並無聲稱應繳的任何重大金額的未繳税款，而本公司及其附屬公司的高級職員亦不知道任何此類申索的依據。本公司的運營方式不符合修訂後的1986年《國税法》第1297節所界定的被動外國投資公司的資格。公司為其共同母公司的合併集團的美國聯邦所得税用途的淨營業虧損 結轉(“NOL”)(如果有的話)不應受到本協議所擬進行的交易的不利影響。本協議擬進行的交易 並不構成守則第382節所指的“所有權變更”，因此 保留了本公司使用此類NOL的能力。

(Bb)內部會計和披露控制。本公司及其各子公司對財務報告保持內部控制(該術語在1934年法案下的規則13a-15(F)中定義)，有效地為財務報告的可靠性和根據公認的會計原則為外部目的編制財務報表提供合理保證， 包括：(I)交易根據管理層的一般或特別授權執行，(Ii)交易 被記錄為必要的，以允許按照國際財務報告準則編制財務報表，並維持資產和負債責任， (Iii)只有在獲得管理層的一般或特別授權的情況下，才允許接觸資產或產生負債 以及(Iv)記錄的資產和負債問責與現有資產和負債按合理間隔進行比較 並針對任何差異採取適當行動。公司維持披露控制和程序(該術語在1934年法案下的規則13a-15(E)中定義)，有效地確保公司在根據1934年法案提交或提交的報告中要求披露的信息在美國證券交易委員會規則和表格中指定的時間段內得到記錄、處理、彙總和報告，包括但不限於，控制和程序旨在確保公司根據1934年法案提交或提交的報告中要求披露的信息被累積並傳達給公司的管理層，包括公司的一名或多名主要高管和一名或多名財務主管，以使 能夠及時做出關於要求披露的決定。本公司或其任何附屬公司概無接獲任何會計師、政府實體或其他人士就本公司或其任何附屬公司的財務報告內部控制的任何潛在重大弱點或重大缺失 部分發出的任何通知或函件。

(cc)資產負債表外 安排。本公司或其任何子公司與未合併 或其他資產負債表外實體之間不存在要求本公司在其1934年法案文件中披露且未披露的交易、安排或其他關係，或 否則可能合理地產生重大不利影響。

(Dd)投資 公司狀態。本公司不是，在證券出售完成後，也不會是“投資公司”、“投資公司”的關聯公司、由“投資公司”或“投資公司”的“關聯人”或“投資公司”的“發起人”或“主承銷商”控制的公司，這些術語在1940年修訂後的《投資公司法》中有定義。

(Ee)確認買方的交易活動。本公司理解並承認：(I)在公開披露交易文件擬進行的交易後，根據交易文件的條款，本公司或其任何子公司均未要求任何買方 同意，也未有任何買方與本公司或其任何子公司達成協議，停止就本公司任何證券進行任何交易或與之有關的任何交易(包括但不限於購買或出售做多和/或做空)，或以本公司發行的證券為基礎的“衍生”證券，或持有任何特定期限的證券；(Ii)任何買方以及任何此類買方直接或間接參與的“衍生”交易的交易對手目前可能在該買方知悉交易文件擬進行的交易之前建立的普通股 中持有“空頭”頭寸；(Iii) 每名買方不得被視為與任何 “衍生”交易中的任何交易對手有任何聯繫或控制；及(Iv)各買方可信賴本公司於轉換、行使或交換(視何者適用而定)證券時，按交易文件的要求及時交付普通股的義務 以實現本公司普通股的交易。本公司進一步理解並承認，在根據新聞稿公開披露交易文件預期的交易(定義如下)後，一個或多個買方可在證券發行期間的不同時間從事套期保值和/或交易活動(包括但不限於可借入普通股的地點和/或預留)，包括但不限於，在認股權證普通股或轉換股的價值和/或數量(按 適用)該等對衝及/或交易活動(包括但不限於可借入普通股的地點及/或預留)(如有)會在進行對衝及/或交易活動時及之後減少現有 股東於本公司的股權的價值。本公司承認，上述對衝及/或交易活動並不構成違反本協議、指定證書、優先認股權證、普通認股權證或任何其他交易文件或與本協議或相關文件有關的任何文件。

(Ff)操縱價格。 本公司或其任何附屬公司，據本公司所知，任何代表其行事的人均未直接或間接(I)採取任何旨在導致或導致穩定或操縱本公司或其任何附屬公司的任何證券的價格的行動，以促進任何證券的出售或轉售，(Ii)出售、競購、購買或 因招攬購買任何證券而支付任何補償，(Iii)因慫恿他人購買本公司或其任何附屬公司的任何其他證券而向任何人士支付或同意支付任何補償 ，或(Iv)就有關本公司或其任何附屬公司的任何證券的研究服務向任何人士支付或同意支付 。

(Gg)美國房地產控股公司。本公司及其任何附屬公司都不是，過去也不是，只要任何證券由任何買方持有，就不應成為守則第897節所指的美國房地產控股公司，本公司及其各附屬公司應應買方的要求予以證明。

(hh)註冊 資格。公司有資格註冊可登記證券（定義見登記權協議） ，以便買方使用根據1933年法案頒佈的表格F—3轉售。

(ii)轉移税。 在截止日期，與本公司根據本協議向每個買方出售的證券的發行、銷售和轉讓有關而需要支付的所有股份轉讓税或其他税（所得税或類似税除外）將全部支付或 ，且所有徵收此類税的法律將得到或將得到遵守。

(Jj)《銀行控股公司法》。本公司或其任何附屬公司均不受經修訂的1956年銀行控股公司法(“BHCA”) 及美國聯邦儲備理事會(“美聯儲”)的監管。本公司及其任何子公司或關聯公司均不直接或間接擁有或控制任何類別有投票權證券的5%(5%)或以上的流通股，或銀行或受BHCA和美聯儲監管的任何實體總股本的25%(25%)或以上。本公司或其任何附屬公司或聯屬公司均不對受BHCA和美聯儲監管的銀行或任何實體的管理或政策施加控制 影響。

(kk)殼牌公司 狀態。本公司不是，也從未是第144（i）條所述或受其約束的發行人。

(ll)非法或未經授權 付款；政治捐款。公司或其任何子公司，以及據公司所知 （在對其高級管理人員和董事進行合理詢問後），本公司或其任何子公司或本公司或任何子公司 與本公司或任何子公司 有關聯或有關聯的任何其他商業實體或企業的任何高級管理人員、董事、僱員、代理人或其他代表，作出或授權任何金錢、財產、 或服務的付款、捐助或饋贈，不論是否違反適用法律，（i）作為回扣或賄賂任何人或（ii）任何政治組織， 或擔任任何民選或選舉性公職的人或任何有志擔任公職的人，但個人政治獻金不涉及 直接或間接使用本公司或其任何子公司的資金。

(mm)洗錢本公司及其子公司遵守且以前從未違反過《2001年美國愛國者法案》以及所有其他適用的美國和非美國反洗錢法律法規，包括但不限於美國外國資產控制辦公室管理的 法律法規和行政命令和制裁計劃，包括但不限於，（i）2001年9月23日題為"封鎖財產和禁止與犯下、威脅犯下或支持恐怖主義者進行交易"的第13224號行政命令（66美聯儲。法規49079（2001））；以及（ii）31 CFR， 副標題B，第五章中所載的任何法規。

(nn)管理 除本協議附件3（nn）中規定的情況外，在過去五年期間，本公司或其任何子公司的現任或前任高級管理人員或董事 ，或據本公司所知，本公司或其任何子公司的現有百分之十（10%）或以上的股東 未成為以下事項的主體：

（i） 根據破產法或任何其他無力償債或暫緩執行法提出的申請，或由法院為該人指定接管人、財務 代理人或類似高級人員，或在提交該申請或該指定之前兩年內，該人為普通合夥人的任何合夥企業，或該人在提交該呈請書或該委任書之時或之前兩年內擔任其執行人員的任何法團或商業協會；

(Ii)刑事訴訟中的定罪或懸而未決的刑事訴訟的指名標的(不包括與酒後駕駛或酒後駕駛無關的交通違法行為)；

㈢ 任何具有管轄權的法院的任何命令、判決或法令（其後未被推翻、中止或撤銷），永久 或暫時禁止或以其他方式限制下列活動：

（1） 作為期貨佣金商、介紹經紀人、商品交易顧問、商品池運營商、場內經紀人、槓桿交易商、受美國商品期貨交易委員會監管的任何其他人或上述任何人的關聯人 ，或作為投資顧問、承銷商、經紀人或證券交易商，或作為關聯人，任何投資公司、銀行、儲蓄和貸款協會或保險公司的董事 或僱員，或從事或繼續與該等活動有關的任何行為 或慣例；

(2) 從事任何特定類型的業務；或

（3） 從事與購買或出售任何證券或商品有關的活動，或與違反證券法或商品法有關的活動；

（iv） 任何當局的任何命令、判決或法令，禁止、暫停或以其他方式 限制任何該等人士從事前款所述任何活動的權利，或與從事任何該等活動的人有聯繫的權利超過六十（60）天；

(V) 民事訴訟中有管轄權的法院、美國證券交易委員會或其他機構作出的違反證券法律、法規或法令的裁決，且美國證券交易委員會或任何其他機構在該民事訴訟或裁決中的判決此後未被推翻、暫停執行或撤銷；或

（vi） 民事訴訟中具有管轄權的法院或商品期貨交易委員會裁定違反 任何聯邦商品法，且該民事訴訟或裁定的判決隨後未被推翻、中止或撤銷。

(oo)股票期權 計劃。本公司授出的每份購股權乃（i）根據本公司適用購股權 計劃的條款授出，及（ii）行使價至少等於該 購股權根據國際財務報告準則及適用法律被視為授出當日普通股的公平市值。根據本公司購股權計劃授出的購股權並無追溯日期。本公司沒有在發佈 或其他關於本公司或其子公司或其財務業績或 前景的重大信息發佈 或其他公開公告之前，有意授予購股權，且 本公司沒有且一直沒有政策或慣例，或有意地將購股權的授予與發佈 或其他公開公告協調。

(pp)與 會計師和律師無異議。公司與公司以前或現在僱用的會計師和律師之間目前不存在或 公司合理預計將出現任何類型的重大分歧，並且公司 目前存在可能影響公司履行 任何交易文件項下義務的能力的會計師和律師的任何費用。此外，在此日期或之前，公司與 其會計師就其先前提交給SEC的財務報表進行了討論。基於這些討論，公司沒有理由 相信它將需要重述任何此類財務報表或其中任何部分。

(QQ)無 個取消資格事件。關於根據本協議將依據1933年法令(以下簡稱“D條例”)第506(B)條發售和出售的證券，本公司、其任何前身、任何關聯發行人、參與本協議擬發行事項的任何董事高管、本公司其他高管、持有本公司20%或以上未償還有表決權股權證券(按投票權計算)的任何實益擁有人、以及在出售時與本公司相關的任何發起人 (該詞定義見1933年法令第405條)。除規則506(D)(2)或(D)(3)所述的取消資格事件外，《1933年法案》規則506(D)(1)(I)至(Viii)中所述的 “髮卡人承保人員”(以及合稱“髮卡人承保人員”)將受到規則506(D)(1)(I)至(Viii)中所述的任何 “不良行為者”資格的取消。本公司已採取合理的 謹慎措施，以確定是否有任何發行人承保人員受到取消資格事件的影響。在適用範圍內，本公司已遵守規則506(E)項下的披露義務，並已向買方提供根據規則提供的任何披露的副本 。

(Rr)其他受保人員 。本公司並不知悉任何人士已獲支付或將獲支付(直接或間接)酬金，以招攬買家或潛在買家出售任何D規例證券。

(ss)沒有其他協議。 公司與任何買方沒有就交易 文件中預期的交易達成任何協議或諒解，交易文件中另有規定。

(tt)公用事業控股法。本公司及其任何子公司均不屬於"控股公司"或"控股公司"的"關聯公司"，這些術語在2005年《公用事業控股法》中定義。

(uu)《聯邦電力法》 本公司或其任何子公司均不受《聯邦電力法》（經修訂）下的“公用事業”監管。

(vv) Cybersecurity. The Company and its Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants that would reasonably be expected to have a Material Adverse Effect on the Company’s business. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); (iv) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person or such, nor any incidents under internal review or investigations relating to the same except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The Company and its Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

(ww) Compliance with Data Privacy Laws. The Company and its Subsidiaries are, and at all prior times were, in compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, the GDPR (EU 2016/679) (collectively, the “Privacy Laws”) except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company and its Subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.

(xx) Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this Agreement and the other Transaction Documents. The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company. All disclosure provided to the Buyers regarding the Company and its Subsidiaries, their businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished by or on behalf of the Company or any of its Subsidiaries is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. All of the written information furnished after the date hereof by or on behalf of the Company or any of its Subsidiaries to each Buyer pursuant to or in connection with this Agreement and the other Transaction Documents, taken as a whole, will be true and correct in all material respects as of the date on which such information is so provided and will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. Each press release issued by the Company or any of its Subsidiaries during the twelve (12) months preceding the date of this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading. No event or circumstance has occurred or information exists with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities, prospects, operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure at or before the date hereof or announcement by the Company but which has not been so publicly disclosed. All financial projections and forecasts that have been prepared by or on behalf of the Company or any of its Subsidiaries and made available to you have been prepared in good faith based upon reasonable assumptions and represented, at the time each such financial projection or forecast was delivered to each Buyer, the Company’s best estimate of future financial performance (it being recognized that such financial projections or forecasts are not to be viewed as facts and that the actual results during the period or periods covered by any such financial projections or forecasts may differ from the projected or forecasted results). The Company acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 2.

4. 公約。

(a)最大努力。 各買方應盡最大努力及時滿足本協議第6條中規定的各項約定和條件。公司應盡最大努力及時滿足本協議第7條規定的各項約定和條件 。

(b)D型和藍天。公司應按照法規D的要求，提交一份有關證券的表格D，並在提交後立即向每個買方提供表格D的副本 。公司應在交割日或之前採取公司合理確定的必要行動，以便根據適用的證券或美國各州的"藍天"法律，在交割日獲得豁免，或使證券有資格在 交割時出售給買方（或 獲得該資格豁免），並應在 截止日期或之前向買方提供任何該等行動的證據。在不限制本協議項下本公司的任何其他義務的情況下，本公司應根據所有適用證券法的要求，及時提交與證券發售和出售有關的所有 備案和報告（包括但不限於，所有適用的聯邦證券法和所有適用的“藍天”法），公司應 遵守所有適用的外國、聯邦、州和地方法律、法規，有關 向買方發售和出售證券的規則、規章等。

(c)報告 狀態。直到買方已出售所有可登記證券之日（“報告期”），公司應及時提交所有要求提交SEC根據1934年法案提交的報告，且 公司不得終止其根據《1934年法案》要求提交報告的發行人的身份，即使《1934年法案》或規則而根據該條例的規定不再要求或以其他方式允許該終止。

(d)收益的使用。 本公司將把出售證券所得款項用於一般企業用途，但不得直接或間接用於 （i）除附表4（d）所述外，清償本公司或其任何子公司的任何債務，（ii）贖回 或回購本公司或其任何子公司的任何證券，或（iii）解決任何未決訴訟。

(e)財務 信息。本公司同意向每一位投資者發送以下信息（定義見《註冊權協議》）在 報告期內（i）（除非通過EDGAR向SEC提交併通過EDGAR向公眾提供以下內容 系統向SEC提交，在向SEC提交後的一（1）個工作日內， 外國發行人在表格6—K上的報告、任何其他中期報告或任何合併資產負債表、損益表、股東權益表和/或現金流量表，除年度以外的任何期間，任何外國發行人在表格6—K上的報告和任何 登記聲明（表格S—8除外）或根據1933年法案提交的修正案，（ii）除非以下內容 通過EDGAR提交給SEC，或通過認可的新聞發佈服務廣泛傳播（如美通社）， 在發佈該新聞稿的同一天，通過電子郵件發送公司或其任何子公司發佈的所有新聞稿的副本，以及 （iii）除非通過EDGAR向SEC提交以下內容， 一般向公司股東提供或提供的任何通知和其他信息的副本，在向股東提供或給予其期間。

(f)在上市 公司應立即確保上市或指定報價（視情況而定）所有可登記證券 在每個國家證券交易所和自動報價系統（如有）上，在此基礎上，普通股被列出或指定報價。（視屬何情況而定）（以正式發佈通知為準），並應保持此類上市或 報價指定（視情況而定）根據 交易文件條款不時在該國家證券交易所或自動報價系統上發行的所有可登記證券。公司應維持普通股在主要市場、紐約證券交易所、美國紐約證券交易所、納斯達克全球市場或納斯達克全球精選市場（各自為"合格市場"）的上市或報價授權（視情況而定）。 公司或其任何子公司均不得采取任何合理預期會導致普通股在合格市場上被摘牌或 停牌的行動。公司應支付與履行本第4條（f）項下的 義務有關的所有費用和開支。

(g) Fees. The Company shall reimburse the lead Buyer for all costs and expenses incurred by it or its affiliates in connection with the structuring, documentation, negotiation and closing of the transactions contemplated by the Transaction Documents (including, without limitation, as applicable, a non-accountable amount of $54,130 for the fees of outside counsel and disbursements of Kelley Drye & Warren LLP, counsel to the lead Buyer, any other reasonable fees and expenses in connection with the structuring, documentation, negotiation and closing of the transactions contemplated by the Transaction Documents and due diligence and regulatory filings in connection therewith) (the “Transaction Expenses”) and shall be withheld by the lead Buyer from its Purchase Price at the Closing; provided, that the Company shall promptly reimburse Kelley Drye & Warren LLP on demand for all Transaction Expenses not so reimbursed through such withholding at the Closing. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, transfer agent fees, DTC (as defined below) fees or broker’s commissions (other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys’ fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment. Except as otherwise set forth in the Transaction Documents, each party to this Agreement shall bear its own expenses in connection with the sale of the Securities to the Buyers.

(h) 證券質押。儘管本協議中有任何相反的規定，本公司承認並同意投資者可以就以證券為擔保的善意保證金協議或其他貸款或融資安排質押 證券。證券質押不應被視為本協議項下證券的轉讓、出售或轉讓 ，任何進行證券質押的投資者均不需要向公司提供任何通知或 根據本協議或任何其他交易文件（包括但不限於 第2（g）節）以其他方式向公司交付任何交付；但投資者及其質押人應遵守本協議第2（g）節的規定，以實現向質押人出售、轉讓或轉讓證券。本公司特此同意 根據證券質押人合理要求的與買方向該質押人質押 證券有關的文件，並簽署和交付。

(i)交易 和其他重要信息的披露。

(i)交易披露 。公司應於上午9時或之前，紐約時間1日（1^ST）在本協議簽訂之日後的 工作日，發佈一份買方合理接受的新聞稿（以下簡稱"新聞稿"）， 披露交易文件中預期交易的所有重要條款。上午9點或之前，紐約時間 第一號（1^ST）本協議簽訂日期後的一個工作日，公司應提交一份格式為6—K的外國發行人報告，以 1934年法案要求的格式描述交易文件所預期交易的所有重要條款，並附上所有重要交易文件（包括但不限於本協議（及本協議的所有附件 ）、優先認股權證的形式、普通認股權證的形式，指定證書的格式和 註冊權協議的格式）（包括所有附件，"6—K文件"）。自 提交6—K文件以來，公司應披露公司或其任何子公司或其各自的任何高級職員、董事、僱員或代理人向任何 買方提供的與交易文件中預期的交易有關的所有重要、非公開信息（如有）。此外，自提交6—K文件之日起， 公司承認並同意，公司、其任何子公司或其任何各自的高級職員、董事、關聯公司、僱員或代理人 為一方，與任何買方或其任何關聯公司為另一方，將終止。

(ii) Limitations on Disclosure. The Company shall not, and the Company shall cause each of its Subsidiaries and each of its and their respective officers, directors, employees and agents not to, provide any Buyer with any material, non-public information regarding the Company or any of its Subsidiaries from and after the date hereof without the express prior written consent of such Buyer (which may be granted or withheld in such Buyer’s sole discretion). In the event of a breach of any of the foregoing covenants, including, without limitation, Section 4(o) of this Agreement, or any of the covenants or agreements contained in any other Transaction Document, by the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees and agents (as determined in the reasonable good faith judgment of such Buyer), in addition to any other remedy provided herein or in the Transaction Documents, such Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such breach or such material, non-public information, as applicable, without the prior approval by the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees or agents. No Buyer shall have any liability to the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees, affiliates, shareholders or agents, for any such disclosure. To the extent that the Company delivers any material, non-public information to a Buyer without such Buyer’s consent, the Company hereby covenants and agrees that such Buyer shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public information. Subject to the foregoing, neither the Company, its Subsidiaries nor any Buyer shall issue any press releases or any other public statements with respect to the transactions contemplated hereby; provided, however, the Company shall be entitled, without the prior approval of any Buyer, to make the Press Release and any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the 6-K Filing and contemporaneously therewith and (ii) as is required by applicable law and regulations (provided that in the case of clause (i) each Buyer shall be consulted by the Company in connection with any such press release or other public disclosure prior to its release). Without the prior written consent of the applicable Buyer (which may be granted or withheld in such Buyer’s sole discretion), the Company shall not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of such Buyer in any filing, announcement, release or otherwise. Notwithstanding anything contained in this Agreement to the contrary and without implication that the contrary would otherwise be true, the Company expressly acknowledges and agrees that no Buyer shall have (unless expressly agreed to by a particular Buyer after the date hereof in a written definitive and binding agreement executed by the Company and such particular Buyer (it being understood and agreed that no Buyer may bind any other Buyer with respect thereto)), any duty of confidentiality with respect to, or a duty not to trade on the basis of, any material, non-public information regarding the Company or any of its Subsidiaries.

(iii) Other Confidential Information. Disclosure Failures; Disclosure Delay Payments. In addition to other remedies set forth in this Section 4(i), and without limiting anything set forth in any other Transaction Document, at any time after the Closing Date if the Company, any of its Subsidiaries, or any of their respective officers, directors, employees or agents, provides any Buyer with material non-public information relating to the Company or any of its Subsidiaries (each, the “Confidential Information”), the Company shall, on or prior to the applicable Required Disclosure Date (as defined below), publicly disclose such Confidential Information on a Report of Foreign Issuer on Form 6-K or otherwise (each, a “Disclosure”). From and after such Disclosure, the Company shall have disclosed all Confidential Information provided to such Buyer by the Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon such Disclosure, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates, on the other hand, shall terminate. In the event that the Company fails to effect such Disclosure on or prior to the Required Disclosure Date and such Buyer shall have possessed Confidential Information for at least ten (10) consecutive Trading Days (each, a “Disclosure Failure”), then, as partial relief for the damages to such Buyer by reason of any such delay in, or reduction of, its ability to buy or sell Common Shares after such Required Disclosure Date (which remedy shall not be exclusive of any other remedies available at law or in equity), the Company shall pay to such Buyer an amount in cash equal to the greater of (I) two percent (2%) of the aggregate Purchase Price and (II) the applicable Disclosure Restitution Amount, on each of the following dates (each, a “Disclosure Delay Payment Date”): (i) on the date of such Disclosure Failure and (ii) on every thirty (30) day anniversary such Disclosure Failure until the earlier of (x) the date such Disclosure Failure is cured and (y) such time as all such non-public information provided to such Buyer shall cease to be Confidential Information (as evidenced by a certificate, duly executed by an authorized officer of the Company to the foregoing effect) (such earlier date, as applicable, a “Disclosure Cure Date”). Following the initial Disclosure Delay Payment for any particular Disclosure Failure, without limiting the foregoing, if a Disclosure Cure Date occurs prior to any thirty (30) day anniversary of such Disclosure Failure, then such Disclosure Delay Payment (prorated for such partial month) shall be made on the second (2nd) Business Day after such Disclosure Cure Date. The payments to which an Investor shall be entitled pursuant to this Section 4(i)(iii) are referred to herein as “Disclosure Delay Payments.” In the event the Company fails to make Disclosure Delay Payments in a timely manner in accordance with the foregoing, such Disclosure Delay Payments shall bear interest at the rate of two percent (2%) per month (prorated for partial months) until paid in full.

(Iv) 就本協定而言，應適用下列定義：

（1） "披露失敗市價"是指，截至任何披露延遲付款日期，計算為 適用披露恢復期（定義見下文）內普通股五（5）個最高VWAP（定義見普通認股權證）之和除以（II）五（5）（該期間，"披露失敗計量期"）的 商數。 所有該等決定均應根據任何股份股息、股份拆分、股份合併、重新分類或類似 交易在該披露失敗計量期間按比例減少或增加普通股。

（2） "披露補償金額"是指，截至任何披露延遲付款日期，（x） （I）披露失敗市價減去（II）根據本協議或任何其他交易文件已發行或 可發行給該買方的任何普通股的每股普通股的最低購買價的乘積，乘以（y）每日 美元總交易量的10%（根據彭博社（定義見認股權證）報告）每個 交易日主要市場上的普通股（定義見普通認股權證）（1）就初始披露延遲付款日期而言，在 期間內，自適用的要求披露日期起至（包括）緊接初始交易日之前的交易日 披露延遲付款日期或（2）對於其他披露延遲付款日期，從 緊接披露延遲付款日期之前的 至緊接該適用 披露延遲付款日期之前的交易日（包括該適用期間，“披露補償期”）。

(3)"所需 披露日期"指（x）如果買方授權交付此類機密信息，（I）如果公司 和買方已就披露此類機密信息的日期（通過電子郵件或其他書面形式證明）達成一致， 該日期或（II）否則，第七（7）^這是）該買方首次收到任何機密 信息之日後的日曆日，或（y）如果該買方未授權交付該機密信息，則第一（1）^ST）營業 買方收到此類機密信息後的第二天。

(j) Additional Registration Statements. Until the Applicable Date (as defined below) and at any time thereafter while any Registration Statement is not effective or the prospectus contained therein is not available for use or any Current Public Information Failure (as defined in the Registration Rights Agreement) exists, the Company shall not file a registration statement or an offering statement under the 1933 Act relating to securities that are not the Registrable Securities (other than a registration statement on Form S-8 or such supplements or amendments to registration statements that are outstanding and have been declared effective by the SEC as of the date hereof (solely to the extent necessary to keep such registration statements effective and available and not with respect to any Subsequent Placement)). “Applicable Date” means the earlier of (x) the first date on which the resale by the Buyers of all the Registrable Securities required to be filed on the initial Registration Statement (as defined in the Registration Rights Agreement) pursuant to the Registration Rights Agreement is declared effective by the SEC (and each prospectus contained therein is available for use on such date) or (y) the first date on which all of the Registrable Securities are eligible to be resold by the Buyers pursuant to Rule 144 (or, if a Current Public Information Failure has occurred and is continuing, such later date after which the Company has cured such Current Public Information Failure).

(k) Additional Issuance of Securities. So long as any Buyer beneficially owns any Securities, the Company will not, without the prior written consent of the Required Holders, issue any Preferred Shares (other than to the Buyers as contemplated hereby) and the Company shall not issue any other securities that would cause a breach or default under the Certificate of Designations or the Common Warrants. The Company agrees that for the period commencing on the date hereof and ending on the date immediately following the 120th calendar day after the Closing Date (the “Restricted Period”), neither the Company nor any of its Subsidiaries shall directly or indirectly issue, offer, sell, grant any option or right to purchase, or otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to purchase or other disposition of) any Convertible Securities (as defined below), any debt, any preferred shares or any purchase rights) (any such issuance, offer, sale, grant, disposition or announcement (whether occurring during the Restricted Period or at any time thereafter) is referred to as a “Subsequent Placement”). Notwithstanding the foregoing, this Section 4(k) shall not apply in respect of the issuance of (i) Common Shares or standard options to purchase Common Shares to directors, officers or employees of the Company in their capacity as such pursuant to an Approved Share Plan (as defined below), provided that the exercise price of any such options is not lowered, none of such options are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that adversely affects any of the Buyers; (ii) Common Shares issued upon the conversion or exercise of Convertible Securities (other than standard options to purchase Common Shares issued pursuant to an Approved Share Plan that are covered by clause (i) above) issued prior to the date hereof, provided that the conversion, exercise or other method of issuance (as the case may be) of any such Convertible Security is made solely pursuant to the conversion, exercise or other method of issuance (as the case may be) provisions of such Convertible Security that were in effect on the date immediately prior to the date of this Agreement, the conversion, exercise or issuance price of any such Convertible Securities (other than standard options to purchase Common Shares issued pursuant to an Approved Share Plan that are covered by clause (i) above) is not lowered, none of such Convertible Securities (other than standard options to purchase Common Shares issued pursuant to an Approved Share Plan that are covered by clause (i) above) are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such Convertible Securities (other than standard options to purchase Common Shares issued pursuant to an Approved Share Plan that are covered by clause (i) above) are otherwise materially changed in any manner that adversely affects any of the Buyers; (iii) the Conversion Shares; provided, that the terms of the Certificate of Designations are not amended, modified or changed on or after the hereof, (iv) the Warrant Preferred Shares; provided, that the terms of the Preferred Warrant are not amended, modified or changed on or after the Closing Date, and (v) the Warrant Common Shares; provided, that the terms of the Common Warrants are not amended, modified or changed on or after the Closing Date (each of the foregoing in clauses (i) through (v), collectively the “Excluded Securities”). “Approved Share Plan” means any employee benefit plan which has been approved by the board of directors of the Company prior to or subsequent to the date hereof pursuant to which Common Shares and standard options to purchase Common Shares may be issued to any employee, officer or director for services provided to the Company in their capacity as such.

(l) Reservation of Shares. So long as any of the Preferred Shares, Preferred Warrants or Common Warrants remain outstanding, the Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than the sum of (i) the maximum number of Conversion Shares issuable upon conversion of the Preferred Shares (assuming for purposes hereof that (w) the Preferred Warrants have been exercised in full, (x) the Preferred Shares are convertible at the Floor Price (as defined in the Certificate of Designations) and (y) any such conversion shall not take into account any limitations on the conversion of the Preferred Shares set forth in the Certificate of Designations), (ii) the maximum number of Warrant Preferred Shares initially issuable upon exercise of the Preferred Warrants (without taking into account any limitations on the exercise of the Preferred Warrants set forth therein) and (iii) the maximum number of Warrant Common Shares initially issuable upon exercise of the Common Warrants (without taking into account any limitations on the exercise of the Common Warrants set forth therein) (collectively, the “Required Reserve Amount”); provided that at no time shall the number of Common Shares reserved pursuant to this Section 4(l) be reduced other than proportionally in connection with any conversion, exercise and/or redemption, as applicable of Preferred Shares and Common Warrants. If at any time the number of Common Shares authorized and reserved for issuance is not sufficient to meet the Required Reserve Amount, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of shareholders to authorize additional shares to meet the Company’s obligations pursuant to the Transaction Documents, in the case of an insufficient number of authorized shares, obtain shareholder approval of an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number of authorized shares is sufficient to meet the Required Reserve Amount.

(m)業務的行為。 公司及其子公司的業務不得違反任何法律、條例或任何政府機構的規章，除非合理預期此類違規行為不會單獨或總體造成重大不利影響 。

(n) Other Preferred Shares; Variable Securities. So long as any Preferred Shares remain outstanding, the Company and each Subsidiary shall be prohibited from effecting or entering into an agreement to effect any Subsequent Placement involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company or any Subsidiary (i) issues or sells any Convertible Securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Shares at any time after the initial issuance of such Convertible Securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such Convertible Securities or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Shares, other than pursuant to a customary “weighted average” anti-dilution provision or (ii) enters into any agreement (including, without limitation, an equity line of credit or an “at-the-market” offering) whereby the Company or any Subsidiary may sell securities at a future determined price (other than standard and customary “preemptive” or “participation” rights). Each Buyer shall be entitled to obtain injunctive relief against the Company and its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

(o)參與權。 在截止日期的第二個週年日（或，如果較早，則為 優先股或優先認股權證沒有發行在外之日的九（9）個月週年日）或之前的任何時間，除非公司首先遵守本第4（o）條的規定，否則公司或其任何子公司均不得直接或間接實施任何後續配售。公司承認並 同意，本第4（o）條所述的權利是公司單獨授予每個買方的權利。

(i) At least five (5) Trading Days prior to any proposed or intended Subsequent Placement, the Company shall deliver to each Buyer a written notice (each such notice, a “Pre-Notice”), which Pre-Notice shall not contain any information (including, without limitation, material, non-public information) other than: (A) if the proposed Offer Notice (as defined below) constitutes or contains material, non-public information, a statement asking whether the Investor is willing to accept material non-public information or (B) if the proposed Offer Notice does not constitute or contain material, non-public information, (x) a statement that the Company proposes or intends to effect a Subsequent Placement, (y) a statement that the statement in clause (x) above does not constitute material, non-public information and (z) a statement informing such Buyer that it is entitled to receive an Offer Notice (as defined below) with respect to such Subsequent Placement upon its written request. Upon the written request of a Buyer within three (3) Trading Days after the Company’s delivery to such Buyer of such Pre-Notice, and only upon a written request by such Buyer, the Company shall promptly, but no later than one (1) Trading Day after such request, deliver to such Buyer an irrevocable written notice (the “Offer Notice”) of any proposed or intended issuance or sale or exchange (the “Offer”) of the securities being offered (the “Offered Securities”) in a Subsequent Placement, which Offer Notice shall (A) identify and describe the Offered Securities, (B) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (C) identify the Persons (if known) to which or with which the Offered Securities are to be offered, issued, sold or exchanged and (D) offer to issue and sell to or exchange with such Buyer in accordance with the terms of the Offer such Buyer’s pro rata portion of 50% of the Offered Securities, provided that the number of Offered Securities which such Buyer shall have the right to subscribe for under this Section 4(o) shall be (x) based on such Buyer’s pro rata portion of the aggregate number of the Preferred Shares purchased hereunder by all Buyers (the “Basic Amount”), and (y) with respect to each Buyer that elects to purchase its Basic Amount, any additional portion of the Offered Securities attributable to the Basic Amounts of other Buyers as such Buyer shall indicate it will purchase or acquire should the other Buyers subscribe for less than their Basic Amounts (the “Undersubscription Amount”), which process shall be repeated until each Buyer shall have an opportunity to subscribe for any remaining Undersubscription Amount.

(ii)為接受 全部或部分要約，買方必須在第五個 （5）月底前向公司提交書面通知^這是)買方收到要約通知後的營業日(“要約期”)，説明買方選擇購買的買方基本金額的部分，如果買方選擇購買所有基本金額，則説明買方選擇購買的認購不足金額(在任何情況下，均為 “接受通知”)。如果所有買受人認購的基本金額少於所有基本金額的總和，則在接受通知書中列出認購金額的買受人，除認購的基本金額外，有權購買其認購的認購金額；然而，如果 認購的基本金額超過所有基本金額的總和與認購的基本金額之間的差額(“可用認購金額”)，則每名已認購任何 認購金額的買家有權只購買可用認購金額中的一部分，該部分僅為該買家的基本金額與所有已認購的基本金額的總和之間的差額，但須受本公司認為合理必要的 舍入所限。儘管有上述規定，如果公司希望在要約期屆滿前修改要約的條款和條件，公司可以向每位買家發出新的要約通知，要約期將於五(5)日屆滿^這是）買方收到 新報價通知後的工作日。

(Iii)自上述要約期屆滿起，本公司應有五(5)個工作日的時間(A)就買方尚未根據最終協議(S)(“後續配售協議”)發出接納通知(“拒絕接受的證券”)的已發行證券的全部或 部分進行要約、發行、出售或交換，但只能向要約通知中所述的受要約人(如其中所述)且僅根據條款和條件(包括但不限於 )，(B)公開宣佈(X)該等後續配售協議已籤立，及(Y)(I)完成該等後續配售協議或(Ii)終止該等後續配售協議，該等報告應以外國發行人以表格6-K格式呈交予美國證券交易委員會的報告形式提交予該等後續配售協議及其中所載的任何文件，如其附件所示。

(Iv) 如果本公司提議出售少於全部被拒絕的證券(任何此類出售應以上文第4(O)(Iii)節規定的方式和條款進行)，則每一買方可自行選擇並全權酌情決定：撤回其接受通知 或將其接受通知中指定的要約證券的數量或金額減少至不少於該買方根據上文第4(O)(Ii)節選擇購買的要約證券的數量或金額乘以一個分數，(I)分子應為公司實際建議發行的要約證券的數量或金額。出售或交換(包括根據本第4(O)節在減持之前將發行或出售給買家的已發行證券)和(Ii)其分母應為已發行證券的原始金額。如果任何買方選擇 減少其接受通知中指定的已發行證券的數量或金額，本公司不得發行、出售或交換超過已減少數量或金額的已發行證券，除非該等證券已根據上文第4(O)(I)節再次向買方要約 。

(V) 在全部或少於全部被拒絕證券的發行、出售或交換完成後，買方應從本公司收購 ，如果買方已根據要約中規定的條款和條件作出選擇，則公司應向買方發行其接受通知中規定的、根據上文第4(O)(Iv)節減少的已要約證券的數量或金額。 在所有情況下，買方購買任何已要約證券均須進行準備，本公司與該買方簽署並交付一份有關該等已發售證券的單獨購買協議，該協議在形式和實質上均令該買方及其律師感到合理滿意。

(Vi) 任何未由買方或其他人根據本協議第4(O)條獲得的要約證券，在根據本協議規定的程序再次向買方要約之前，不得發行、出售或交換。

(Vii)本公司和每名買方同意，如果任何買方選擇參與要約，(X)關於該要約的後續配售協議或與此相關的任何其他交易文件(統稱為“後續配售文件”) 均不應包括任何條款或條款，據此，買方應被要求同意對公司任何證券的任何交易 的任何限制，或被要求同意根據或與 相關的任何修訂或終止，或授予任何豁免、免除等，先前與本公司訂立的任何協議或從本公司收到的任何文件，及(Y)該等後續配售文件所載的任何登記權利應在所有重大方面與登記權利協議所載的登記權利相類似。

(Viii) 儘管第4(O)節有任何相反規定，除非買方另有約定，否則公司應 以書面形式向買方確認關於後續配售的交易已被放棄，或應公開披露其發行要約證券的意向，在任何一種情況下，以使買方不會在第五(5)日之前擁有任何 重大非公開信息的方式。^這是)遞送優惠通知後的營業日。如果到這樣的第五個 (5^這是）交易日，未公開披露與要約證券有關的交易，且 該買方未收到關於放棄該交易的通知，該交易應被視為 放棄，且該買方不應擁有與本公司或其任何 子公司有關的任何重大非公開信息。如果公司決定就已發行證券進行此類交易，公司應向該 買方提供另一份要約通知，該買方將再次享有本第4（o）條所述的參與權。除非第4（o）（ii）節最後一句明確規定，否則本公司 不得在任何六十（60）天內向買方交付超過一份此類要約通知。

（ix） 本第4（o）條所載的限制不適用於任何除外證券的發行。 公司不得通過向一個買方提供未向 所有買方提供的條款或條件來規避本第4（o）條的規定。

(p)稀釋 發行。只要任何優先股、優先認股權證或普通認股權證仍然未發行，公司不得， 以任何方式，訂立或影響任何稀釋發行（定義見指定證書），如果該 稀釋發行的影響導致公司必須在轉換任何優先股或行使任何普通股時發行 在不違反公司在 主要市場規則或條例下的義務的情況下，對超過公司在轉換優先股和行使普通認股權證時可能發行的普通股數量的任何普通股發出認股權證。

（q） 被動外國投資公司。公司應開展其業務，並應促使其子公司開展 各自業務，其方式應確保公司不會被視為本守則第1297條所指的被動外國投資 公司。

(r) 贖回和現金股息的限制。只要任何優先股尚未發行，未經買方事先明確書面 同意（指定證書要求的除外），公司不得直接或間接贖回、宣佈或支付任何現金股息或公司任何證券的分配。

(s)公司 存在。只要任何買方實益擁有任何優先股、優先認股權證或普通認股權證，公司 不應成為任何基本交易（定義見指定證書）的一方，除非公司遵守 指定證書和普通認股權證中規定的基本交易的適用條款。

(t)轉換和練習 程序。每一種形式的演習通知（定義見普通認股權證）包括在普通認股權證內， 練習通知的形式（定義見優先認股權證）包括於優先認股權證及轉換通知的格式（如指定證書中的定義 ）包含在指定證書中，列出了 所需的全部程序買方以行使優先認股權證或普通認股權證或轉換優先股。除 第5（d）條另有規定外，買方行使其優先 認股權證或普通認股權證或轉換其優先股時，無需提供額外法律意見、其他信息或指示。公司應履行優先認股權證和普通 認股權證的行使以及優先股的轉換，並應分別按照指定證書、優先認股權證和普通認股權證中規定的條款、條件和期限交付轉換股份、認股權證優先股和認股權證普通 認股權證。

(u)條例M. 本公司將不會採取1934年法案下的條例M禁止的與本協議所考慮的證券分銷有關的任何行動。

(V)公開徵集。 本公司、其任何聯屬公司(定義見1933年法令第501(B)條)或任何代表本公司行事的人士，或該等聯屬公司，將不會以任何形式的一般徵詢或一般廣告的方式，徵集買賣證券的要約，包括：(I)在任何報章、雜誌或類似媒體上或在電視或廣播上發表的任何廣告、文章、通知或其他通訊；以及(Ii)與會者受到任何一般徵集或一般廣告邀請的任何研討會或會議。

(W)融合。本公司、其任何關聯公司(定義見1933年法案下的規則501(B))、代表公司行事的任何人或該關聯公司的任何 不會出售、要約出售、或就任何證券(定義見《1933年法案》)徵求購買或以其他方式進行談判的要約，而該證券將與證券銷售整合在一起，其方式將要求根據1933年法案註冊證券或根據主要市場的規則和法規要求股東批准，本公司將採取一切適當或必要的行動，以確保其發行的其他證券不會因1933年法案或主要市場的規則和法規的目的而與本公司擬發行的證券整合在一起。

(X)取消資格通知 個項目。本公司將在以下事項結束日期前書面通知買方：(I)與任何發行人承保人員有關的任何取消資格事件，以及(Ii)隨着時間推移可能成為與發行人 承保人員有關的任何取消資格事件的任何事件。

(Y)成交文件。 在成交日期後十四(14)個日曆日或之前，公司同意向每位買方和Kelley Drye&Warren LLP交付或安排交付一套完整的已籤立交易成交文件、證券和根據本條款第7條或其他規定必須交付給任何一方的任何其他文件。

5. 寄存器；傳輸代理指令；圖例。

(A)註冊紀錄冊。本公司應在其主要執行辦公室(或本公司向每位證券持有人發出的通知所指定的本公司其他辦事處或機構)保存一份關於優先股、優先認股權證和普通權證的登記冊，公司應在其中記錄優先股、優先認股權證和普通權證的發行人的姓名和地址(包括每個受讓人的姓名和地址)、該人持有的優先股總數、根據優先股條款可發行的轉換股份數目、因行使該人士所持優先認股權證而可發行的認股權證優先股總數及因行使該人士所持普通權證而可發行的認股權證普通股總數。公司應開放登記冊，並在營業時間內隨時開放，以供任何買方或其法定代表人檢查。

(b) Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent and any subsequent transfer agent (as applicable, the “Transfer Agent”) in a form acceptable to each of the Buyers (the “Irrevocable Transfer Agent Instructions”) to issue certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“DTC”), registered in the name of each Buyer or its respective nominee(s), for the Conversion Shares and the Warrant Common Shares in such amounts as specified from time to time by each Buyer to the Company upon conversion of the Preferred Shares or the exercise of the Common Warrants (as the case may be). The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5(b), and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the Company to its transfer agent with respect to the Securities, and that the Securities shall otherwise be freely transferable on the books and records of the Company, as applicable, to the extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a sale, assignment or transfer of the Securities in accordance with Section 2(g), the Company shall permit the transfer and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves Conversion Shares or Warrant Common Shares sold, assigned or transferred pursuant to an effective registration statement or in compliance with Rule 144, the transfer agent shall issue such shares to such Buyer, assignee or transferee (as the case may be) without any restrictive legend in accordance with Section 5(d) below. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5(b) will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section 5(b), that a Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required. The Company shall cause its counsel to issue the legal opinion referred to in the Irrevocable Transfer Agent Instructions to the Company’s transfer agent on each Effective Date (as defined in the Registration Rights Agreement). Any fees (with respect to the transfer agent, counsel to the Company or otherwise) associated with the issuance of such opinion or the removal of any legends on any of the Securities shall be borne by the Company.

(c)傳説每個 買方都明白證券已發行（或將在轉換股份、認股權證 優先股和認股權證普通股的情況下發行）根據1933年法案和 適用的州證券法的註冊或資格豁免，且除下文所述者外，證券應帶有任何州"藍天"法要求的任何圖例，以及基本上以以下形式的限制性圖例（並且可以 針對此類股票的轉讓發出停止轉讓指令）：

[無論是 本證書所代表的資產的發行和銷售，還是這些資產所組成的資產 [敞篷車][可操練]已 ][本證書所代表的證券尚未]根據1933年《土地法》（經修訂）或 適用的州土地法註冊。（I）在沒有 （A）根據經修訂的1933年房產法案，或（B） 顧問意見的情況下，不得出售、出售、轉讓或轉讓房產（如公司要求），以公司可合理接受的形式，根據上述法案或（II）除非根據上述法案第144條或第144A條出售或有資格出售，否則不需要進行該註冊。儘管 上述規定，這些擔保物可能與由這些擔保物擔保的本地信用保證金或其他貸款或融資安排有關。

(D)刪除 個傳説。證明證券的證書無需包含上文第5(C)節所述的圖例或任何其他圖例：(I)當涉及轉售此類證券的註冊聲明(包括註冊聲明)根據1933年法案生效時，(Ii)根據規則144出售此類證券(假設轉讓人不是本公司的關聯公司)，(Iii)如果此類證券有資格根據規則144出售、轉讓或轉讓(前提是買方向公司提供有資格出售此類證券的合理保證)，根據規則 144項下的轉讓或轉讓(不包括買方律師的意見)，(Iv)與銷售、轉讓或其他轉讓有關的(br}規則144項下的除外)，前提是該買方以一般可接受的形式向公司提供該買方的律師意見，大意是，該等證券的出售、轉讓或轉讓可以在沒有根據1933年法案的適用要求進行登記的情況下進行，或者(V)如果1933年法案的適用要求不需要上述説明(包括但不限於，控制美國證券交易委員會發布的司法解釋和聲明)。如果根據前述規定不需要圖例，則在買方向本公司或轉讓代理(通知本公司)交付代表該證券的傳奇憑證(背書或附有股份權力)後，本公司應不遲於兩(2)個交易日(或根據1934年法案或其他適用法律、規則或條例的規定，在買方向本公司交付代表該等證券的傳奇憑證向本公司交付該等傳奇憑證之日起為交易結算日期)。以及以其他必要的形式影響重新發行和/或轉讓(如果適用)，連同上述第5(D)節可能要求的買方按照該買方的指示進行的任何其他交付，或者：(A) 只要本公司的轉讓代理參與DTC快速自動證券轉讓計劃(“FAST”)，並且該等證券是轉換股票或認股權證普通股，貸記買方有權通過 其在託管系統的存取款獲得該買方或其指定人在DTC的餘額賬户的普通股的總數，或(B)如果公司的轉讓代理沒有參與FAST，則向該買方簽發並 交付(通過信譽良好的隔夜快遞)代表該證券的證書，該證書不受所有 限制性和其他傳説的限制。以該買方或其指定人的名義登記的(要求將有關信用記入該買方或該買方指定人持有DTC的餘額賬户的日期，或根據前述規定須向該買方或該買方指定人交付的證書在此稱為“規定交付日期”，以及該普通股實際交付給該買方或該買方指定人的 日期，如 適用，為“股份交付日期”)。本公司應負責任何轉讓代理費或DTC費用 與任何證券的發行或任何證券相關的任何傳説的刪除。

(e) Failure to Timely Deliver; Buy-In. If the Company fails to fail, for any reason or for no reason, to issue and deliver (or cause to be delivered) to a Buyer (or its designee) by the Required Delivery Date, either (I) if the Transfer Agent is not participating in FAST, a certificate for the number of Warrant Preferred Shares, Conversion Shares or Warrant Common Shares (as the case may be) to which such Buyer is entitled and register such Warrant Preferred Shares, Conversion Shares or Warrant Common Shares (as the case may be) on the Company’s share register or, if the Transfer Agent is participating in FAST, to credit the balance account of such Buyer or such Buyer’s designee with DTC for such number of Conversion Shares or Warrant Common Shares (as the case may be) submitted for legend removal by such Buyer pursuant to Section 5(d) above or (II) if the Registration Statement covering the resale of the Conversion Shares or Warrant Common Shares (as the case may be) submitted for legend removal by such Buyer pursuant to Section 5(d) above (the “Unavailable Shares”) is not available for the resale of such Unavailable Shares and the Company fails to promptly, but in no event later than as required pursuant to the Registration Rights Agreement (x) so notify such Buyer and (y) deliver the Conversion Shares or Warrant Common Shares, as applicable, electronically without any restrictive legend by crediting such aggregate number of Conversion Shares or Warrant Common Shares (as the case may be) submitted for legend removal by such Buyer pursuant to Section 5(d) above to such Buyer’s or its designee’s balance account with DTC through its Deposit/Withdrawal At Custodian system (the event described in the immediately foregoing clause (II) is hereinafter referred as a “Notice Failure” and together with the event described in clause (I) above, a “Delivery Failure”), then, in addition to all other remedies available to such Buyer, the Company shall pay in cash to such Buyer on each day after the Share Delivery Date and during such Delivery Failure an amount equal to 2% of the product of (A) the sum of the number of Common Shares not issued to such Buyer on or prior to the Required Delivery Date and to which such Buyer is entitled, and (B) any trading price of the Common Shares selected by such Buyer in writing as in effect at any time during the period beginning on the date of the delivery by such Buyer to the Company of the applicable Conversion Shares or Warrant Shares (as the case may be) and ending on the applicable Share Delivery Date. In addition to the foregoing, if on or prior to the Required Delivery Date either (I) if the Transfer Agent is not participating in FAST, the Company shall fail to issue and deliver a certificate to a Buyer and register such Common Shares on the Company’s share register or, if the Transfer Agent is participating in FAST, credit the balance account of such Buyer or such Buyer’s designee with DTC for the number of Common Shares to which such Buyer submitted for legend removal by such Buyer pursuant to Section 5(d) above (ii) below or (II) a Notice Failure occurs, and if on or after such Trading Day such Buyer purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction of a sale by such Buyer of Common Shares submitted for legend removal by such Buyer pursuant to Section 5(d) above that such Buyer is entitled to receive from the Company (a “Buy-In”), then the Company shall, within two (2) Trading Days after such Buyer’s request and in such Buyer’s discretion, either (i) pay cash to such Buyer in an amount equal to such Buyer’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any, for the Common Shares so purchased) (the “Buy-In Price”), at which point the Company’s obligation to so deliver such certificate or credit such Buyer’s balance account shall terminate and such shares shall be cancelled, or (ii) promptly honor its obligation to so deliver to such Buyer a certificate or certificates or credit the balance account of such Buyer or such Buyer’s designee with DTC representing such number of Common Shares that would have been so delivered if the Company timely complied with its obligations hereunder and pay cash to such Buyer in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Conversion Shares or Warrant Shares (as the case may be) that the Company was required to deliver to such Buyer by the Required Delivery Date multiplied by (B) the lowest Closing Sale Price (as defined in the Warrants) of the Common Shares on any Trading Day during the period commencing on the date of the delivery by such Buyer to the Company of the applicable Conversion Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii). Nothing shall limit such Buyer’s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing Common Shares (or to electronically deliver such Common Shares) as required pursuant to the terms hereof. Notwithstanding anything herein to the contrary, with respect to any given Notice Failure and/or Delivery Failure, this Section 5(e) shall not apply to the applicable Buyer the extent the Company has already paid such amounts in full to such Buyer with respect to such Notice Failure and/or Delivery Failure, as applicable, pursuant to the analogous sections of the Certificate of Designations or Warrant, as applicable, with respect to the Preferred Shares or Common Warrants, as applicable, then held by such Buyer.

(f)快速合規。 當任何普通認股權證尚未到期時，公司應保留一名參與FAST的轉讓代理人。

6. 公司出售義務的條件。

本公司 在交易結束時向每個買方發行和出售初始優先股、優先認股權證和普通認股權證的義務， 在交易結束日期或之前，須滿足下列各項條件，前提是這些條件適用於公司的 本公司可隨時自行決定，向每位買方發出事先書面通知，以放棄該等權利。

（a） 該買方應簽署其作為一方的每一份其他交易文件，並將其交付給公司。

（b） 該買方和其他各買方應已向公司交付購買初始優先股、優先認股權證和普通認股權證的購買價格（如果是任何買方，則減去 根據第4（g）條扣留的金額）， 根據資金流量函通過電匯立即可用資金在交易結束時購買。

(c)買方的陳述和 保證自作出之日起和截止日期起在所有重要方面都應真實和正確，如同 最初是在當時作出的（除特定日期的陳述和保證外，自該特定日期起，這些陳述和保證應為真實和正確 ），且該買方應履行，在所有重大方面滿足並遵守本協議要求該 買方在截止日期或之前履行、滿足或遵守的契約、協議 和條件。

7. 每個買方購買義務的條件。

每個買方 在交易完成時購買其初始優先股、優先認股權證和普通認股權證的義務， 在交易完成日期或之前滿足以下條件，條件是這些條件僅為每個買方的利益 ，且買方可隨時自行酌情通過向公司提供事先書面通知予以放棄：

（a） 公司應已正式簽署並向買方交付其作為一方的每份交易文件，且 公司應已正式簽署並向買方交付（i）買方清單第（3）欄中 買方名稱對面所列的優先股總數，（ii）優先認股權證，最初收購的認股權證優先股總數為買方附表第（4）欄相對買方名稱所列，及（iii）普通認股權證 ，以初始收購最多為買方附表第（5）欄 中相對買方名稱所列的認股權證普通股總數，在每種情況下，根據本協議由買方在成交時購買。

（b） 該買方應已收到公司的美國律師和公司的英屬維爾京羣島律師的意見， 日期為截止日期，並採用買方可接受的形式。

（c） 公司應向買方交付一份不可撤銷的轉讓代理人指示的副本，該指示應交付給公司的轉讓代理人並由其書面確認。

（d） 公司應在截止日期後十（10）天內向買方提交一份證明公司在該 實體成立管轄區成立和良好信譽的證書，該證書由該成立管轄區的國務大臣（或類似辦事處）簽發。

（e） 公司應在截止日期後十（10）天內向買方提交證明公司作為外國公司的資格 和良好信譽的證書，該證書由公司開展業務的每個司法管轄區的國務大臣（或類似的辦公室）頒發 並被要求具備該資格。

（f） 公司應在截止日期後十（10）天內向買方提交經英屬維爾京 羣島國務大臣認證的公司章程的認證副本。

（g） 公司應向買方提交一份證書，該證書採用買方可接受的形式，由 公司祕書籤署，日期為截止日期，證明（i）公司 董事會以買方可合理接受的形式通過的符合第3（b）條的決議，（ii）本公司的組織章程細則及（iii）本公司的組織章程大綱，各自在交易結束時有效。

（h） 公司的每一項陳述和保證，自作出之日和截止之日起均應真實無誤 ，猶如最初在當時作出一樣（在特定日期時聲明和保證除外，在該特定日期時應是真實和正確的）且公司應在所有方面履行、滿足和遵守契約， 公司在截止日期或之前必須履行、滿足或遵守的協議和條件。該買方 應已收到一份由公司首席執行官正式簽署的、日期為截止日期的證書，該證書具有上述效力 以及該買方可能合理要求的其他事項，其格式應為買方可接受。

（i） 公司應已向買方交付一份公司轉讓代理人的信函，該信函證明在緊接交割前的交割日已發行的普通股數量。

（j） 普通股（A）應指定報價或上市（如適用）在主要市場上進行交易，且（B）截至收盤日，美國證券交易委員會或主要市場未 暫停主要市場的交易，且美國證券交易委員會或主要市場在收盤日也未受到暫停威脅，（I）SEC或主要市場以書面形式 或（II）低於主要市場的最低維護要求。

（k） 公司應已獲得出售證券所需的所有政府、監管機構或第三方同意和批准（如有），包括但不限於主要市場（如有）所要求的同意和批准。

(L) 任何具有司法管轄權的法院或政府實體不得頒佈、訂立、公佈或認可任何法規、規則、法規、行政命令、法令、裁決或禁令，以禁止完成交易文件所預期的任何交易 。

(M) 自本協議簽署之日起，不得發生任何事件或事件系列合理地造成或導致重大不利影響。

(N) 本公司應已取得主要市場的批准，以上市或指定(視乎情況而定)換股股份及認股權證普通股上市或指定上市。

(O) 該買方應已收到由本公司行政總裁正式簽署的以本公司信箋抬頭的函件，列明各買方的電匯金額及本公司的電匯指示(“資金流向函件”)。

(P) 本公司及其附屬公司應已按買方或其律師的合理要求，向買方交付與本協議擬進行的交易有關的其他文件、文書或證書。

8. 終止。

如果買方在本協議簽訂之日起五(5)天內未完成交易，則該買方有權在該日期交易結束後的任何時間終止其在本協議項下的義務，而不對任何其他方承擔責任；但是，(I)如果由於買方違反本協議而導致本協議預期的交易未能在該日期前完成，則該買方不能根據本第8條享有終止本協議的權利，並且(Ii)放棄出售和購買優先股、優先認股權證和普通認股權證應僅適用於提供此類書面通知的買方，此外，任何此類終止 均不影響本協議項下本公司向買方償還上文第4(G)節所述費用的任何義務。第8條中包含的任何內容均不得被視為免除任何一方違反本協議或其他交易文件的條款和條款的任何責任，或損害任何一方強制任何其他方具體履行其在本協議或其他交易文件下的義務的權利。

9. 其他。

(A)適用法律；管轄權；陪審團審判。有關本協議的解釋、有效性、執行和解釋的所有問題應由紐約州的國內法律管轄，不適用於任何法律選擇或法律衝突的規定或規則(無論是紐約州還是任何其他司法管轄區)，這些條款或規則將導致適用紐約州以外的任何 司法管轄區的法律。公司在此不可撤銷地接受位於曼哈頓區紐約市的州法院和聯邦法院的專屬管轄權，以裁決本協議項下或與本協議或任何其他交易文件相關的任何爭議，或根據本協議或因此而擬進行的任何交易，並且 在此不可撤銷地放棄、並同意不在任何訴訟、訴訟或程序中主張其本人不受任何此類法院的管轄權管轄、該等訴訟、訴訟或程序是在不方便的法院提起或 該訴訟、訴訟或程序的地點不合適。每一方特此不可撤銷地放棄以面交方式送達法律程序文件，並同意在任何此類訴訟、訴訟或法律程序中送達法律程序文件，方法是將其副本郵寄至根據本協議向其送達該等通知的地址，並同意此類送達應構成充分有效的法律程序文件及其通知的送達。 公司現指定附表9(A)所列人員為其在紐約的法律程序文件送達代理人。此處包含的任何內容均不得視為以任何方式限制以法律允許的任何方式送達過程的任何權利。本協議中包含的任何內容均不得被視為或阻止任何買方在任何其他司法管轄區對本公司提起訴訟或採取其他法律行動，以追討本公司對該買方的義務，或執行對該買方有利的判決或其他法院裁決。每一方在此不可撤銷地放棄其可能擁有的任何權利，並同意不要求對本協議、任何其他交易文件或本協議、任何其他交易文件或本協議、任何其他交易文件或本協議、任何其他交易文件或由此預期的任何交易引起的任何爭議進行陪審團審判。選擇紐約州的法律作為本協定的管轄法律是一種有效的法律選擇，將在英屬維爾京羣島有管轄權的法院提起的任何訴訟中得到承認並生效，但下列法律除外：(1)該法院認為具有程序性的法律，(2)税收或刑法，或(3)其適用與公共政策不一致的法律，因為該術語是根據英屬維爾京羣島的法律解釋的。選擇紐約州的法律作為本協議的管轄法律將得到印度主管法院的認可，但須遵守印度的相關民事訴訟程序要求。根據英屬維爾京羣島、印度或紐約州的法律，公司或其各自的任何財產、資產或收入不享有任何豁免權，不享有任何法律訴訟、訴訟或法律程序的豁免權，不享有在任何英屬維爾京羣島和印度、紐約或美國聯邦法院的管轄範圍內給予任何法律訴訟、訴訟或法律程序的濟助的豁免權，不享有在判決之時或判決之前送達法律程序文件、扣押財產或協助執行判決的豁免權。或其他法律程序或程序，以便在任何此類法院就其在本協議項下或引起的或與本協議有關的義務、責任或任何其他事項給予任何救濟或執行判決；此外，在公司或其任何財產、資產或收入可能已經或此後可能有權在任何此類法院享有任何此類豁免權的情況下，公司特此在法律允許的範圍內放棄此類權利，並同意按照本協議和其他交易文件的規定進行救濟和強制執行。

(B)副本。 本協議可簽署兩份或兩份以上相同的副本，所有副本應被視為同一份協議，並在雙方簽署副本並交付給另一方後生效。如果任何簽名 是通過傳真或包含已執行簽名 頁的可移植文檔格式(.pdf)文件的電子郵件交付的，則該簽名頁應為簽字方(或其代表簽署此類簽名) 產生有效且具有約束力的義務，其效力和效果與該簽名頁為其正本一樣。

(c)標題；性別。 本協議的標題僅為方便參考，不構成本協議的一部分，也不影響本協議的解釋。 除非上下文另有明確説明，否則此處的每個代詞應被視為包括陽性、陰性、中性、單數 及其複數形式。術語“包括”、“包括”、“包括”和類似含義的詞語應廣泛解釋，就好像後面跟着“不限於”。術語“在此”、“在此”、“在此”和類似含義的詞語指的是整個協議，而不僅僅是其中的條款。

(d) Severability; Maximum Payment Amounts. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without implication that the following is required or applicable), it is the intention of the parties that in no event shall amounts and value paid by the Company and/or any of its Subsidiaries (as the case may be), or payable to or received by any of the Buyers, under the Transaction Documents (including without limitation, any amounts that would be characterized as “interest” under applicable law) exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to any Buyer, or collection by any Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such applicable law, such obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of such Buyer, the Company and its Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by the applicable law. Such adjustment shall be effected, to the extent necessary, by reducing or refunding, at the option of such Buyer, the amount of interest or any other amounts which would constitute unlawful amounts required to be paid or actually paid to such Buyer under the Transaction Documents. For greater certainty, to the extent that any interest, charges, fees, expenses or other amounts required to be paid to or received by such Buyer under any of the Transaction Documents or related thereto are held to be within the meaning of “interest” or another applicable term to otherwise be violative of applicable law, such amounts shall be pro-rated over the period of time to which they relate.

(E)整個協議； 修正案。本協議、本協議及其附件所附的其他交易文件和附表及附件，以及本協議和本協議中提及的文書，取代買方、本公司、其子公司、其關聯公司和代表其行事的人之間之前達成的所有其他口頭或書面協議，包括但不限於任何買方與 就普通股或證券進行的任何交易，以及本協議和本協議中包含的其他事項，以及其他 交易文件。本協議所附的附表和證物以及本協議和本協議中引用的文書 僅包含雙方對本協議和協議中所涉事項的完整理解；但是， 本協議或任何其他交易文件中包含的任何內容不應(或應被視為)(I)對任何買方在本協議日期之前與公司或其任何子公司就其先前在本公司進行的任何投資訂立的任何 協議或從該公司或其任何子公司收到的任何文書 產生任何影響，或(Ii)放棄、更改、修改或 在任何方面修訂本公司或其任何子公司的任何義務、或任何買方或任何其他人的任何權利或利益。本公司及/或其任何附屬公司與任何買方在本協議日期前訂立的任何協議，或本公司及/或其任何附屬公司於本協議日期前從本公司及/或其任何附屬公司收到的任何文書，而所有 該等協議及文書將繼續完全有效。除本協議或本協議另有規定外，本公司或任何買方均不就該等事宜作出任何陳述、保證、契諾或承諾。 No provision of this Agreement may be amended other than by an instrument in writing signed by the Company and the Required Holders (as defined below), and any amendment to any provision of this Agreement made in conformity with the provisions of this Section 9(e) shall be binding on all Buyers and holders of Securities, as applicable; provided that no such amendment shall be effective to the extent that it (A) applies to less than all of the holders of the Securities then outstanding or (B) imposes any obligation or liability on any Buyer without such Buyer’s prior written consent (which may be granted or withheld in such Buyer’s sole discretion). No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party, provided that the Required Holders may waive any provision of this Agreement, and any waiver of any provision of this Agreement made in conformity with the provisions of this Section 9(e) shall be binding on all Buyers and holders of Securities, as applicable, provided that no such waiver shall be effective to the extent that it (1) applies to less than all of the holders of the Securities then outstanding (unless a party gives a waiver as to itself only) or (2) imposes any obligation or liability on any Buyer without such Buyer’s prior written consent (which may be granted or withheld in such Buyer’s sole discretion). No consideration (other than reimbursement of legal fees) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration also is offered to all of the parties to the Transaction Documents, all holders of the Preferred Shares, all holders of Preferred Warrants or all holders of the Common Warrants (as the case may be). The Company has not, directly or indirectly, made any agreements with any Buyers relating to the terms or conditions of the transactions contemplated by the Transaction Documents except as set forth in the Transaction Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any financing to the Company, any Subsidiary or otherwise. As a material inducement for each Buyer to enter into this Agreement, the Company expressly acknowledges and agrees that (x) no due diligence or other investigation or inquiry conducted by a Buyer, any of its advisors or any of its representatives shall affect such Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company’s representations and warranties contained in this Agreement or any other Transaction Document and (y) unless a provision of this Agreement or any other Transaction Document is expressly preceded by the phrase “except as disclosed in the SEC Documents,” nothing contained in any of the SEC Documents shall affect such Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company’s representations and warranties contained in this Agreement or any other Transaction Document.

(F)通知。根據本協議條款要求或允許發出的任何通知、同意、豁免或其他通信必須以書面形式發出，並且 將被視為已送達：(I)在收到時，當面送達；(Ii)在收到時，通過電子郵件發送(前提是該已發送的電子郵件由發送方存檔(無論是電子郵件還是其他形式)，並且發送方沒有從收件人的電子郵件服務器收到無法將該電子郵件遞送給該收件人的自動生成的消息)； 或(Iii)存款後一(1)個工作日提供隔夜快遞服務，並在每種情況下指定正確的 收件人。此類通信的郵寄地址和電子郵件地址應為：

如果是對公司：

Lytus Technologies Holdings PTV。珠穆朗瑪峯A翼601號有限公司
安得赫裏Mahakali石窟路(東)

印度孟買400 093
電話：(284)494-2810
注意：首席執行官
電子郵件：darmesh@lytuscorp.com

將副本(僅供參考)發送至：

普華永道現金管理有限公司
7時代廣場
紐約，NY 10036
電話：(212)326-0820
注意：M.Ali潘傑瓦尼，Esq.
電子郵件：ali.panjwani@pryorcashman.com

如果發送給傳輸代理：

VStock Transfer，LLC
老佛爺廣場18號
伍德米爾，紐約11598
電話：(212)828-8436
注意：勞倫斯·萊特
電子郵件：lawrence@vstock fer.com

如果發給買方，其郵寄地址和電子郵件地址載於買方時間表，並將複印件送交買方時間表上規定的買方代表，

將副本(僅供參考)發送至：

Kelley Drye&Warren LLP
3世貿中心
格林威治街175號
紐約，NY 10007
電話：(212)808-7540
注意：邁克爾·A·阿德爾斯坦，Esq.
電子郵件：madelstein@kelley drye.com

或其他郵寄地址和/或電子郵件地址，和/或接收方在變更生效前五(5)天向對方發出書面通知所指定的其他人的注意，但僅應向Kelley Drye&Warren LLP提供發送給牽頭買方的通知的副本。根據上文第(I)、(Ii)或(Iii)款的規定，收件人對上述通知、同意、豁免或其他通信作出的書面確認(A)、發送者包含時間、日期和收件人的電子郵件以機械或電子方式生成的(B)或(C) 隔夜快遞服務提供的(C) 收據，應分別作為當面送達、電子郵件收據或通宵快遞服務收據的可推翻證據。

(G)繼承人和受讓人。本協議對雙方及其各自的繼承人和受讓人(包括任何優先股、優先認股權證和普通權證的任何購買者)的利益具有約束力並符合其利益。未經所需持有人的事先書面同意，公司不得轉讓本協議或本協議項下的任何權利或義務，包括但不限於以基礎交易(如優先認股權證中的定義)的方式轉讓(除非公司遵守優先認股權證中規定的基礎交易的適用條款)，基本交易(如普通權證所界定)(除非本公司遵守普通權證所載有關基本交易的適用規定)或基本交易(如指定證書所界定的)(除非本公司遵守有關指定證書所載有關基本交易的適用規定)。買方可在未經公司同意的情況下轉讓其在本協議項下的部分或全部與其任何證券的轉讓相關的權利，在這種情況下，該受讓人應被視為本協議項下的買方。

(h)沒有第三方受益人。 本協議旨在為本協議各方及其各自的允許繼承人和受讓人的利益而訂立，不為 任何其他人的利益，本協議的任何條款不得由第9（k）條所述的受償人以外的任何其他人執行。

(I)生存。 陳述、保證、協議和契諾在關閉後繼續有效。每一買方僅對其在本合同項下的陳述、保證、協議和契諾負責。

(j)進一步的ASIAN。 每一方均應實施並執行或促使實施並執行所有此類進一步行動和事項，並應簽署和交付所有其他協議、證書、文書和文件，如任何其他一方可能合理要求，以實現本協議的意圖 和實現本協議的目的，並完成本協議預期的交易。

(K)賠償。 作為每個買方簽署和交付交易文件並獲得交易文件項下證券的代價，除了本公司在交易文件下的所有其他義務外，公司應保護、保護、賠償任何證券的每一位買家和每位持有人及其所有股東、合夥人、成員、高級管理人員、董事、員工和直接或間接投資者以及任何前述人士的代理人或其他代表(包括但不限於與本協議預期進行的交易有關的人員)(統稱為， “賠償對象“)因任何和所有訴訟、訴訟理由、訴訟、索賠、損失、費用、罰款、費用、法律責任和損害賠償以及與此相關的費用(不論任何此類賠償對象是否為本合同項下尋求賠償的訴訟的 一方)，以及因公司或任何子公司在任何交易文件中作出的任何失實陳述或違反任何陳述或保證而招致的合理律師費和支出 (”賠償責任“) 。(Ii)違反任何交易文件所載本公司或任何附屬公司的任何契諾、協議或義務，或(Iii)第三方對該受償人提出或提出的任何訴因、訴訟、法律程序或索賠(為此包括代表本公司或任何附屬公司提起的衍生訴訟)，或涉及因下列原因而引起或導致的 受償人：(A)任何交易文件的籤立、交付、履行或強制執行，(B)任何直接或間接資助或全部或部分融資的交易，(C)該買方根據第4(I)條作出的任何適當披露，或(D)該買方或證券持有人根據交易文件擬進行的交易而作為本公司的投資者或作為本協議的一方(包括但不限於，作為強制令或其他衡平法救濟的任何 訴訟或訴訟中的利害關係方)的地位。在本公司的上述承諾可能因任何原因而無法強制執行的範圍內，本公司應盡最大努力支付和履行適用法律允許的每項 賠償責任。除本文另有規定外，與第9(K)條規定的權利和義務有關的機制和程序應與《註冊權協議》第6條規定的相同。

(L)施工。 本協議中使用的語言將被視為雙方選擇的表達相互意圖的語言，不對任何一方適用 嚴格的施工規則。任何特定的陳述或保證都不應限制更一般的陳述或保證的一般性或適用性。凡提及本協議中與普通股有關的股價、普通股和任何其他 數字時，應根據本協議日期後發生的與普通股有關的任何股份拆分、股份分紅、股份合併、資本重組或其他類似交易自動進行調整。儘管本協議中有任何相反規定，為免生疑問，本協議中包含的任何內容均不構成針對借入本公司證券的 安排的任何陳述或擔保或禁止採取任何行動，以便於該買方 (或其經紀人或其他財務代表)在未來進行賣空或類似交易。

(M)補救措施。每名買方以及在買方轉讓其在本協議項下的權利和義務的情況下，每名證券持有人應享有交易文件中規定的所有權利和補救措施，以及這些持有人在任何時候根據任何其他協議或合同獲得的所有權利和補救措施，以及這些持有人根據任何法律享有的所有權利。根據本協議任何條款 擁有任何權利的任何人應有權具體執行此類權利(無需張貼保證書或其他擔保)、因違反本協議任何條款而追回損害賠償 以及行使法律授予的所有其他權利。此外，本公司認識到，如果本公司或其任何附屬公司未能履行、遵守或履行其或該附屬公司在交易文件項下的任何或全部義務(視情況而定)，任何法律上的補救措施都不足以給予買方足夠的救濟。因此，公司 同意，在任何此類案件中，買方應有權從任何有管轄權的法院獲得具體履約和/或臨時、初步和永久禁令或 其他衡平法救濟，而無需證明實際損害和 無需張貼保證金或其他擔保。本協議和其他交易文件中提供的補救措施應是累積的 ，並且除了法律上或衡平法上根據本協議和其他交易文件提供的所有其他補救措施(包括特定履行法令和/或其他強制令救濟)。

(n)退出權。 儘管有任何相反的規定，（且不限制交易文件的任何類似條款），當 任何買方行使交易文件項下的權利、選擇、要求或選擇權，且公司或任何子公司未在交易文件規定的期限內及時履行其相關義務時，該買方可撤銷或撤回，在不影響其未來行動和權利的情況下， 不時在書面通知本公司或該附屬公司（視情況而定）後，自行酌情決定 不時在不影響本公司或該附屬公司的書面通知、要求或選擇 。

(O)預留款項； 貨幣。如果本公司根據本協議或根據任何其他交易向任何買方支付一筆或多筆款項 文件或任何買方根據本協議或本協議執行或行使其權利，且該等付款或該等強制執行或行使的收益或其任何部分隨後被宣佈無效、被宣佈為欺詐性或優惠性、被公司追回、由公司、受託人、接管人或任何其他人根據任何法律(包括但不限於任何破產法、外國、州或聯邦法律)收回、返還或以其他方式恢復。除非另有明確説明，本協議和其他交易文件中提及的所有美元金額均以美元為單位，本協議和其他交易文件中提及的所有金額均以美元為單位。所有以其他貨幣計價的金額(如果有)應按照計算日期的匯率折算為等值美元金額 。“匯率”是指根據本協議將兑換成美元的任何金額的貨幣，是指在相關計算日期在《華爾街日報》上公佈的美元匯率。

(p)判斷貨幣

(I) 如果為了在任何司法管轄區的任何法院獲得或執行與本協議或任何其他交易文件有關的對本公司不利的判決，有必要將本協議項下到期的美元金額兑換成任何其他貨幣(在本第9(P)節中稱為“判斷貨幣”)， 應按緊接前一個交易日的匯率進行兑換：

(1) 在紐約法院或任何其他司法管轄區法院進行的任何法律程序中，實際支付應付款項的日期 在該日期作出的上述轉換：或

(2) 就任何其他司法管轄區法院的任何法律程序而言，外地法院裁定的日期(依據第9(P)(I)(2)條作出上述轉換的日期，以下稱為“判決轉換日期”)。

(Ii)如果在上文第9(P)(I)(2)節所述的任何司法管轄區法院的任何訴訟中，判決轉換日期與實際支付到期金額的日期之間的匯率發生變化，適用一方應支付必要的調整金額，以確保以判決貨幣支付的金額在按付款日期的匯率轉換時，將以判決或司法命令中規定的判決貨幣金額按判決轉換日期的匯率產生可購買的美元金額 。

(Iii)本條款項下本公司應付的任何 金額將作為單獨債務到期，且不受就本協議或任何其他交易文件項下或就本協議或就本協議或任何其他交易文件而應支付的任何其他金額而獲得的判決的影響。

(Q)買方義務和權利的獨立性 。每個買方在交易文件下的義務是多個的，而不是與任何其他買方的義務連帶的，任何買方都不以任何方式對履行任何交易文件下的任何其他買方的義務負責。此處或任何其他交易文件中包含的任何內容，以及任何買方根據本協議或該協議採取的任何行動，均不應被視為構成買方，本公司承認買方並未因此構成合夥企業、協會、合資企業或任何其他類型的集團或實體，或建立買方以任何方式一致或作為集團或實體的推定，公司不應就交易文件或任何事項預期的此類義務或交易提出任何此類索賠。本公司承認，買方並非一致或作為一個團體行事，本公司不應就該等義務或交易文件所預期的交易提出任何此類索賠。每個買方根據交易文件購買證券的決定是由該等買方獨立於任何其他買方作出的。每一買方均承認，沒有其他買方就該買方在本協議項下的投資 擔任該買方的代理，也不會有任何其他買方在監督該買方在證券方面的投資或執行其在交易文件下的權利方面擔任該買方的代理。本公司及每名買方確認 每名買方已獨立參與本公司及其附屬公司在徵詢本公司本身的法律顧問及顧問的意見下就擬進行的交易進行的談判。每一買方均有權獨立保護和執行其權利，包括但不限於本協議或任何其他交易文件所產生的權利，任何其他買方沒有必要為此目的而作為額外的一方加入任何訴訟程序。使用單一協議完成本協議擬進行的證券買賣完全由本公司控制，而不是任何買方的行動或決定 ，這完全是為了方便本公司及其附屬公司，而不是因為任何買方要求或要求這樣做。雙方明確理解並同意，本協議和其他交易文件中包含的各項規定僅在公司、各子公司和買方之間，而不是在公司、其子公司和買方之間，而不是在買方之間和買方之間。

(R)税項。

(I)在不限制本協議任何其他條款的情況下，公司在本協議項下的任何和所有付款均應免税和清償，且不得扣除任何和所有現有或未來的税項、徵費、附加費、附加費、扣除額、收費或扣繳，以及與此有關的所有負債(統稱為“税項”)，除非公司根據任何適用法律被要求扣繳或扣減任何税項金額 。如果公司應就本合同項下向任何買方支付的任何款項扣除任何税款或 ，(I)應支付的金額應增加應支付金額 必須增加的金額(“全額”)，以確保在進行所有必要的 扣減(包括適用於全額的扣減)後，該買方將收到的金額等於如果沒有進行此類扣減的情況下將收到的金額。(Ii)本公司應作出該等扣減，及(Iii)本公司應在規定時間內向有關政府當局支付扣繳或扣減的全部款項。應本公司的要求，該買方應向本公司提供法律規定的填妥並簽署的表格或證書，作為 申請豁免或減免根據本協議支付的任何税款的依據。

(Ii) 此外，本公司同意根據適用法律向相關政府當局支付因根據本協議進行的任何付款或與本協議的執行、交付、登記或履行有關的或與本協議有關的任何當前或 未來的印花税或單據税或任何其他消費税或財產税、收費或類似費用(“其他 税”)。

(Iii)公司應在支付税金和其他税金或每個買方合理接受的其他付款證據後，立即向每一買方交付關於本協議項下應付的任何税項和其他税項的正式收據(如果有)。

(Iv) 如果公司未按照第9(R)條的規定支付任何金額，公司應在提出書面要求後十(Br)(10)個日曆日內賠償每位買方因此而向有關政府當局或其他有關政府當局支付的全部税款或其他税款，以及任何相關利息或罰款。

(V) 本第9(R)條規定的公司義務在本協議終止和支付本協議項下應支付的所有金額後繼續有效。

[簽名頁面如下]

茲證明，自上文首次寫明的日期起，各買方和本公司已使各自在本協議上的簽字頁正式簽署。

茲證明，自上文首次寫明的日期起，各買方和本公司已使各自在本協議上的簽字頁正式簽署。

買家明細表